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III. Abstract 
 
Neuroinflammation is a complex and multifactorial response of the central 
nervous system (CNS) to trauma, infection and neurodegenerative diseases 
orchestrated by specialized immune cells (microglial and astrocytes). In particular, 
microglia, the main resident immune cells of the CNS, undergo rapid “activation” 
in response to noxious stimuli, releasing a plethora of inflammatory and 
potentially neurotoxic soluble factors, such as cytokines [e.g., interleukin (IL)-1β, 
IL-6 and tumor necrosis factor (TNF)-α], chemokines and reactive oxygen and 
nitrogen species (e.g., nitric oxide). Although an efficient microglial immune 
response is necessary and critical for proper resolution of pathological events, it is 
clear that an excessive activation of these cells contributes to neuronal cell 
damage in neurodegenerative and psychiatric disorders. However, the molecular 
mechanism(s) by which these cells exert their deleterious effects on neurons 
remain poorly understood. Recent evidence suggests that microglial cells can be 
“activated” in response to a systemic inflammatory stimulus. For example, a 
single peripheral administration of the bacterial endotoxin lipopolysaccharide 
(LPS), the main component of Gram-negative bacteria walls, in adult mice, can 
induce microglial activation and an inflammatory state in the CNS that persists 
long after peripheral stimulus has decline.  
Identification of molecules which prevent or down-regulate microglial 
inflammatory responses or direct microglia towards a protective anti-
inflammatory phenotype could prove efficacious in neurodegenerative diseases in 
which inflammation is implicated. Recently, increasing interest has focused on 
identifying natural compounds with potential inhibitory effects on microglial 
activation and subsequent inflammatory processes. Among these compounds, 
curcumin (diferuloylmethane), the main bioactive component isolated from the 
rhizome of the turmeric plant (Curcuma longa) with multiple pharmacological 
effects, including anti-inflammatory activities, possesses neuroprotective 
properties against many neurodegenerative conditions. 
The principal focus of this doctoral project has been the study of the possible anti-
inflammatory effect of curcumin in an in vivo model of neuroinflammation based 
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on a single systemic LPS injection. Young adult mice were intraperitoneally 
injected with a single dose of LPS (0.5 or 5 mg/kg) or vehicle and then tested for 
“sickness behavior” (e.g., changes in body weight and food intake), mRNA (real-
time RT-PCR) and protein (enzyme-linked immunosorbent assay, ELISA) 
expression of pro-inflammatory mediators and microglia morphological changes 
(immune-staining with the microglial marker ionized calcium binding adaptor 
molecule 1) in different brain areas. Both LPS doses induced a significant 
decrease in food intake and body weight within the first 4 days, followed by a 
gradual recovery to control values; however, only 5 mg/kg LPS significantly 
increased TNF-α, IL-1β, IL-6, COX-2 and iNOS gene expression 2 h post-
injection. Pre-treatment with 50 mg/kg curcumin (orally administered by gavage 
for 2 consecutive days before LPS injection) facilitated the recovery from sickness 
behavior (anorexia and weight loss), suppressed LPS-induced microglial 
morphological changes and increased of mRNA levels of TNF-α, IL-1β and COX-
2 in all brain areas, while limiting expression of IL-6 and iNOS to more selected 
brain regions.  
Possible neuroprotective properties of curcumin were also investigated. In 
particular, mRNA expression of brain-derived neurotrophic factor (BDNF), 
known to play a key role in the regulation of neuronal function, as well as in 
learning and memory processes. Its reduced expression, described in numerous 
neurodegenerative disorders, contributes to the onset of structural abnormalities 
and functional damage in the CNS. LPS treatment reduced mRNA levels of 
BDNF in all brain areas analyzed up to 7 days after treatment. Pre-treatment with 
50 mg/kg curcumin restored BDNF gene expression 24 hours after LPS injection, 
while a higher dose of curcumin (100 mg/kg) completely restored the expression 
of BDNF 2 hours after the inflammatory stimulus.  
Finally, behavioral tests demonstrated that LPS induced motor and memory 
impairments, that persisted even when the inflammatory process had been solved. 
Moreover, curcumin reversed motor deficits induced by LPS.  
Taken together, these data show that curcumin can prevent neuroinflammation by 
modulating the expression of brain pro-inflammatory mediators in vivo and also 
suggest a potential role of curcumin as a neuroprotective molecule able to restore 
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BDNF levels and behavioral impairments under inflammatory conditions. In 
conclusion, curcumin represents a promising lead compound to discover new drug 
candidates, with improved therapeutic efficacy in the treatment of 
neurodegenerative and age-related diseases with an inflammatory etiology. 
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1. Introduction 
 
1.1 Inflammation and neuroinflammation 
Inflammation is a complex cascade of self-defensive response to infectious or 
sterile tissue damage and has the physiological purpose of restoring tissue 
homeostasis [Medzhitov, 2010]. However, uncontrolled or unresolved 
inflammation can drive tissue damage, giving rise to a plethora of chronic 
inflammatory diseases, including neurodegenerative and autoimmune diseases 
with eventual loss of organ function [Nathan and Ding, 2010]. In fact, signs of 
persistent and unresolved inflammation are not merely typical of classical 
inflammatory diseases but they represent also intrinsic features of a wide spectrum 
of human conditions not previously thought to have an inflammatory component 
[Serhan et al., 2007]. This, justifies the increasing interest in studying 
inflammatory processes. In this context, an important milestone has been achieved 
with the knowledge that the resolution of an acute inflammatory condition is 
crucial to avoid chronic persistent inflammation and ensure proper return to 
homeostasis [Lawrence and Gilroy, 2007]. Inflammation underlies a wide variety 
of physiological and pathological processes. Although the pathological aspects of 
many types of inflammation are well characterized, their physiological functions 
are mostly elusive [Medzhitov, 2008]. 
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Figure 1. Causes and physiological and pathological outcomes of inflammation. 
Depending on the trigger, the inflammatory response has a different physiological 
purpose and pathological consequences. Of the three possible initiating stimuli, only 
infection induced inflammation is coupled with the induction of an immune response 
(modified from Medzhitov, 2008). 
 
 
Typically, the acute inflammatory response, triggered by infection or tissue 
damage, implies the coordinated migration of the blood components (plasma and 
leukocytes) to the site of infection or tissue damage (Fig.1) [Majno and Joris, 
2004; Kumar et al., 2003]. This response has been well characterized for 
microbial infections, especially bacterial, in which, the innate immune system is 
activated by binding to receptors known as Toll-like (TLR) and NOD (nucleotide-
binding-protein oligomerization domain)-like receptors(NLRs), among others 
[Barton, 2008]. Tissue resident macrophages and mast cells became activated and 
release a plethora of inflammatory mediators, including chemokines, cytokines, 
vasoactive amines, eicosanoids and products of proteolytic cascades which elicit 
an inflammatory exudate locally with selective extravasation of neutrophils 
afforded by the inducible ligation of endothelial-cell selectins with integrins and 
chemokine receptors on leukocytes [Poeber and Sessa, 2007]. Once reached 
damaged tissue, neutrophils become activated, either by direct contact with 
pathogens or through the actions of cytokines secreted by tissue resident cells, and 
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begin to fight the invading agents by releasing the toxic contents of their granules, 
which contain reactive oxygen species (ROS) and reactive nitrogen species, 
proteinase 3, cathepsin G and other molecules [Nathan, 2006]. These highly 
potent effectors do not discriminate between microbial and host targets, so 
collateral damage to host tissues is unavoidable [Nathan, 2002]. The successful 
resolution of the acute inflammatory response is mainly mediated by resident and 
recruited macrophages producing transforming growth factor-β and growth factors 
as well as anti-inflammatory lipid mediators (lipoxins, resolvins and protectins) 
which inhibits the recruitment of neutrophils and promote the recruitment of 
monocytes and results in the elimination of the infectious agents followed by 
tissue remodelling and repair [Serhan and Savill, 2005; Serhan, 2007].  
If the acute inflammatory response fails to eliminate the pathogen, the 
inflammatory process persists and acquires new characteristics, recruiting 
macrophages, and in case of infection, T cells. If the combined effect of these 
cells is still inadequate, a chronic inflammatory state takes place. Persistent injury 
or infection, prolonged exposure to a toxic agent, undegradable foreign bodies and 
autoimmune diseases can induce a chronic inflammatory state characterized by 
long duration, lymphocyte, plasma cell and macrophage infiltration, tissue 
destruction (mediated by inflammatory cells)and unsuccessful repair with fibrosis 
and angiogenesis [Lawrence and Gilroy, 2007]. The complex architecture of 
systemic chronic inflammation plays a central role in the development of chronic 
diseases, such as neurodegenerative and autoimmune diseases, although the exact 
mechanism is still poorly understood. 
In the central nervous system (CNS), the inflammatory response to various stimuli 
(trauma, infection, etc.) represents a highly regulated biological program that 
enables the innate and adaptive immune systems to effectively fight pathogens, 
restores cerebral damages and preserves tissue homeostasis. In this context, 
cellular and molecular immune components such as specialized glial cells 
(microglia and astrocytes) are the main actors [Glass et al., 2010; Hirsh and 
Hunot, 2009].In particular, microglia, the resident innate immune cells of the 
CNS, undergo rapid “activation” in response to injurious stimuli, producing a 
plethora of inflammatory and potentially neurotoxic soluble factors, such as 
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cytokines [e.g., interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α], 
chemokines and reactive oxygen and nitrogen species (e.g., nitric oxide) (Fig. 2).  
 
 
 
 
Figure 2. Cells involved in neuroinflammation and neurodegeneration. Under 
pathological conditions, microglial cells become activated and express iNOS, 
leading to the production and release of NO free radicals. These cells also have 
upregulated expression and activation of NADPH oxidase, leading to the production 
of high amounts of O
2–
 free radicals. In turn, O
2–
 and NO free radicals might react to 
generate the highly reactive ONOO
–
, which can cause oxidative damage to several 
proteins within dopaminergic neurons. Reactive astrocytes express increased 
concentrations of myeloperoxidase, might directly inflict oxidative damage to 
dopaminergic neurons through, for example, amine conversion into chloramine. 
Apart from these non-cell-autonomous mechanisms of neuronal cell death, 
inflammatory-associated oxidative stress might also originate from the damaged 
dopaminergic neurons through COX2 expression.(from Hirsch and Hunot, 2009) 
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Although an efficient microglial immune response is necessary and critical for 
host defence, it is clear that over-activation of microglia contribute to neuronal 
cell damage [Norden et al., 2015]. In response to a peripheral infection, microglial 
cells produce pro-inflammatory cytokines that act on the brain to cause what is 
called the “acute phase response (APR)” and “sickness behavior”. The latter is 
characterized by endocrine, autonomic and behavioral changes and includes fever, 
reductions in activity, food intake and social interactions [Dantzer et al., 2008]. 
When activation of the peripheral immune system continues unabated, such as 
during systemic infections, cancer or autoimmune diseases, the ensuing immune 
signalling to the brain can lead to an exacerbation of sickness and the 
development of a chronic state of neuroinflammation. During a normal infection, 
neuroinflammation and the resulting adaptive sickness behaviour persists only for 
several days. However, if these responses become exaggerated or prolonged, the 
outcomes may become established, leading to neurodegeneration, cognitive 
impairment and depression [Dantzer et al., 2008]. Recent evidence suggests that 
microglia can be “activated” in response to a systemic inflammatory stimulus. 
One important and well-known model exhibiting a unique gene expression profile 
in the brain and an exaggerated neuroinflammatory response is the activation of 
the peripheral innate immune system by a single peripheral injection of 
lipopolysaccharide (LPS), the major component of Gram-negative bacterial wall. 
In adult mice LPS administration can lead to microglial activation and CNS 
inflammation that persists long after peripheral events have declined [Qin et al., 
2007; Noh et al., 2014].  
 
1.2 Inducers and mediators of neuroinflammation 
In the brain, the inflammatory pathway is regulated by a wide range of inducers 
and mediators that form complex regulatory networks. Inducers initiate the 
inflammatory response and activate specialized sensors, which then elicit the 
production of specific sets of mediators. The mediators, in turn, alter the 
functional states of tissues and organs, like the brain, in a way that allows them to 
adapt to the conditions indicated by the particular inducer of inflammation. 
Inducers of neuroinflammation can be exogenous or endogenous agents. 
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1.2.1 Endogenous inducers 
Endogenous inducers are signals produced by stressed, damaged or otherwise 
malfunctioning of brain tissue. The identity and characteristics of these signals are 
poorly defined but they probably belong to various functional classes according to 
the nature and the degree of tissue anomalies on which they report. During 
necrotic neuronal death, for example, the integrity of the plasma membrane is 
disrupted, resulting in the release of certain cellular constituents, including ATP, 
K
+ 
ions, uric acid, HMGB1 (high-mobility group box 1 protein) and several 
members of the S100 calcium-binding protein family (S100A8, S100A9 and 
S100A12) [Rock and Kono, 2008; Bianchi, 2007]. ATP binds to purinoceptors 
(including P2X7) at the surface of microglia and macrophages, resulting in K
+
 ion 
efflux, and can cooperate with other signals to activate the NALP3 inflammasome 
[Halle et al., 2008]. ATP also activates nociceptors (which are sensory receptors), 
thereby reporting tissue injury to the nervous system [Keller et al., 2008].  
HMGB1 and S100A12 engage the receptor RAGE (advanced glycation end-
product-specific receptor; also known as AGER), which (at least in the case of 
HMGB1) cooperates with TLRs to induce an inflammatory response. S100A8 and 
S100A9 signal through TLR4 [Hofmann et al., 1999; Vogl et al., 2007]. It should 
be noted that, although intracellular proteins are thought to be passively released 
when the plasma membrane of necrotic cells is disrupted, numerous intracellular 
proteins can be secreted by a non-canonical (endoplasmic-reticulum–Golgi-
independent) pathway. In light of this finding, it will be necessary to examine 
whether inflammatory intracellular proteins are passively released from necrotic 
cells or secreted by a dependent mechanism. Finally, damage to the cerebral 
vascular endothelium allows plasma proteins and platelets to gain access to 
extravascular cerebral spaces [Poeber and Sessa, 2007]. 
 
1.2.2 Exogenous inducers 
Exogenous inducers consist of two groups: non-microbial and microbial .Non-
microbial exogenous inducers include allergens, irritants, foreign bodies and toxic 
compounds [Kumar et al., 2003]. Microbial inducer can be classified into two 
groups: virulence factors and pathogen-associated molecular patterns 
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(PAMPs).Virulence factors are a class of microbial inducers not linked directly by 
dedicated receptors. Instead, the effects of their activity, particularly their adverse 
effects on host tissues, are responsible for triggering the inflammatory response. 
Typical activities of virulence factors can be detected by specialized sensors. For 
example, the pore-forming exotoxins produced by Gram-positive bacteria are 
detected by the NALP3 (NACHT-, leucine-richrepeat- and pyrin-domain-
containing protein) inflammasome, which is sensitive to the efflux of K
+
 ions that 
results from pore formation [Mariathasan et al., 2006]. 
The main class of microbial inducer, PAMPs, is a limited and defined set of 
conserved molecular patterns that is carried by all microorganisms of a given class 
(Gram-positive and -negative bacteria, DNA and RNA viruses, fungi and 
protozoa) [Medzhitov and Janeway, 1997]. PAMPs are specifically recognized by 
pattern recognition receptors (PRRs), a crucial parts of the innate immune 
reaction. The intracellular signalling cascades triggered by these PRRs lead to 
transcriptional expression of inflammatory mediators that coordinate the 
elimination of pathogens and infected cells. However, aberrant activation of this 
system leads to immunodeficiency, septic shock, and seems to be related with the 
onset of neuroinflammatory diseases [Lehnardt, 2010].A variety of intracellular 
and extra-cellular PRRs are known up to date. Among others, the growing family 
includes TLRs, NLRs, RIG-like receptors (RLRs) and C-type lectin receptors 
(CLRs) [Takeuchi and Akira, 2010] (Table 1). 
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Table 1. PRRs and their ligands. 
 
Germline-encoded pattern recognition receptors (PRRs) are responsible for sensing the 
presence of microorganisms. They do this by recognizing structures conserved among 
microbial species, which are called pathogen-associated molecular patterns (PAMPs). 
Recent evidence indicates that PRRs are also responsible for recognizing endogenous 
molecules released from damaged cells, termed damage-associated molecular patterns 
(DAMPs). Currently, four different classes of PRR families have been identified. These 
families include transmembrane proteins such as the Toll-like receptors (TLRs) and C-
type lectin receptors (CLRs), as well as cytoplasmic proteins such as the retinoic acid-
inducible gene (RIG)-I-like receptors (RLRs) and NOD-like receptors (NLRs) (from 
Takeuchi and Akira, 2010). 
 
The RLR family is composed of RIG-I, melanoma differentiation-associated gene 
5 (MDA5) and LGP2[Takeuchi and Akira, 2009]. RLRs are composed of two N-
terminal caspase recruitment domains (CARDs), a central DEAD box 
helicase/ATPase domain and a C-terminal regulatory domain. They are localized 
in the cytoplasm and recognize the genomic RNA of dsRNA viruses and dsRNA 
generated as the replication intermediate of ssRNA viruses. The expression of 
RLRs is greatly enhanced in response to type I IFN stimulation or virus infection 
[Yoneyama and Fujita, 2008]. RLRs play a major role in pathogen sensing of 
RNA virus infection to initiate and modulate antiviral immunity. The RLRs detect 
viral RNA ligands or processed self RNA in the cytoplasm to triggers innate 
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immunity and inflammation and to impart gene expression that serves to control 
infection. Importantly, RLRs cooperate in signalling crosstalk networks with 
TLRs and other factors to impart innate immunity and to modulate the adaptive 
immune response [Loo and Gale, 2011]. 
The NLR family consists of cytoplasmic pathogen sensors that are composed of a 
central nucleotide-binding domain and C-terminal leucine-rich repeats. The N-
terminal portions of most NLRs harbor protein-binding motifs, such as CARDs, a 
pyrin domain, and a baculovirus inhibitor of apoptosis protein repeat (BIR) 
domain. NLRs harboring a pyrin domain or a BIR domain in their N terminus are 
not involved in the transcriptional activation of inflammatory mediators and are 
components of the inflammasome that regulates caspase1 activation [Inohara et 
al., 2005]. NOD1 and NOD2, which harbor CARDs in addition to NOD and LRR 
domains, activate nuclear factor-kappa B (NF-κB) via an adaptor, RIP2/ RICK. 
NOD1 and NOD2 induce transcriptional upregulation of pro-inflammatory 
cytokine genes. NOD1 and NOD2 recognize the structures of bacterial 
peptidoglycans, g-D-glutamyl-mesodiamino pimelic acid (iE-DAP) and muramyl 
dipeptide (MDP), respectively. As TLRs also recognize bacterial peptidoglycan 
components, TLRs and NODs synergistically activate pro-inflammatory cytokine 
production [Franchi et al., 2009]. 
CLRs comprise a transmembrane receptor family characterized by the presence of 
a carbohydrate-binding domain. CLRs recognize carbohydrates on 
microorganisms such as viruses, bacteria, and fungi. CLRs either stimulate the 
production of pro-inflammatory cytokines or inhibit TLR-mediated immune 
complexes [Geijtenbeek and Gringhuis, 2009]. 
Out of this intricate system of innate immune receptors, the TLR family is one of 
the best characterized PRR families and is responsible for sensing invading 
pathogens outside of the cell and in intracellular endosomes and lysosomes [Glass 
et al., 2010; Akira et al., 2006].Mammalian TLRs were initially discovered 
because of their sequence similarities to Toll involved in Drosophila dorso-ventral 
embryonic development and antifungal immunity [Nüsslein-Volhard and 
Wieschaus, 1980; Lemaitre et al., 1996]. In 1997, Medzhitov and colleagues 
cloned a human homolog of the Drosophila Toll protein, now known as TLR4, 
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and showed that Toll signalling was able to stimulate adaptive immune responses 
[Medzhitov et al., 1997]. Shortly after, the Toll gene was discovered to be an 
important component for the detection of microbes in Drosophila melanogaster, 
as well as increasing studies demonstrated that TLR4 mediated the inflammatory 
response to LPS in mice [Poltorak et al., 1998; Poltorak et al., 2000 ]. This led to 
the identification of the target molecule of LPS on the cellular surface of 
macrophages. These discoveries substantially extended the knowledge of 
pathogen-mediated intra-cellular signal transduction, and were crucial for 
understanding the mechanisms that govern innate immunity [Bode et al., 2012]. 
To date, ten different TLRs have been discovered in humans and 12 in mice; for 
most of them their specific ligands are known. These receptors have the same 
basic structure of a type 1 transmembrane glycoprotein receptor. However, 
whereas some TLRs are localized at the cell membrane (TLR1, 2, 4, 5, 6 and 10), 
others are anchored in the endosome (TLR3, 7, 8 and 9) and therefore lie 
intracellularly [Kumar et al., 2009].TLRs are characterized by N-terminal leucine-
rich repeats (LRRs) and a transmembrane region followed by a cytoplasmic 
Toll/IL-1R homology (TIR) domain. Different TLRs recognize the different 
molecular patterns of microorganisms and self-components (Table 1).In recent 
years it has become clear that activation of TLRs is not restricted to the initiation 
of innate and adaptive immune reactions. In the gastrointestinal tract for instance, 
TLRs and their interaction with commensal microflora seem to be required for the 
maintenance of normal homeostasis [Rakoff-Nahoum et al., 2004]. On the other 
hand, aberrant activation of TLR pathways has been implicated in various chronic 
and autoimmune diseases affecting the CNS, the gastrointestinal tract, kidneys, 
skin, lungs and joints. Thereby, not only exogenous but rather endogenous ligands 
have been suggested to act as TLR activators. Evidence that intracellular proteins 
or products of protein cleavage can act as endogenous ligands for TLRs supported 
the hypothesis that TLRs are not only of importance in mediating a response to 
infections but to stress, damage and death of cells in general [Gallucci et al., 1999; 
Shi et al., 2000] 
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1.2.3 Mediators of neuroinflammation 
Inducers of inflammation trigger the production of numerous inflammatory 
mediators, which in turn alter the functionality of many tissues and organs. Many 
of the inflammatory mediators have effects in common on the vasculature and on 
the recruitment of leukocytes. These mediators can be derived from plasma 
proteins or secreted by cells [Majno and Joris, 2004; Kumar et al., 2003]. The 
cellular mediators can be produced by specialized leukocytes (particularly tissue-
resident macrophages and mast cells) or by cells present in local tissues. Some 
mediators (such as histamine and serotonin) are preformed and stored in the 
granules of mast cells, basophils and platelets. Others are preformed and circulate 
as inactive precursors in the plasma. The plasma concentration of these mediators 
can increase markedly as a result of increased secretion of the precursors by 
hepatocytes during the acute-phase response. Other mediators are produced 
directly in response to appropriate stimulation by inducers of inflammation. 
Inflammatory mediators can be classified into seven groups according to their 
biochemical properties [Majno and Joris, 2004; Kumar et al., 2003]: vasoactive 
amines, vasoactive peptides, fragments of complement components, lipid 
mediators, cytokines, chemokines and proteolytic enzymes.  
In particular, lipid mediators (eicosanoids and platelet-activating factors) are 
derived from phospholipids, such as phosphatidylcholine, that are present in the 
inner leaflet of cellular membranes. After activation by intracellular Ca
2+
 ions, 
cytosolic phospholipase A2 generates arachidonic acid and lysophosphatidic acid, 
the precursors of the two classes of lipid mediator, from phosphatidylcholine. 
Arachidonic acid is metabolized to form eicosanoids either by cyclooxygenase 
(COX-1 andCOX-2), or by lipoxygenases, which generate leukotrienes and 
lipoxins2.Lipoxins (and dietary ω3-fatty-acid-derived resolvins and protectins) 
inhibit inflammation and promote resolution of inflammation, and tissue repair 
[Serhan and Savill, 2005]. COX catalyses the first committed step in the 
prostanoids synthesis, a large family of arachidonic acid metabolites comprising 
PGs, prostaclyclin and tromboxanes. The prostaglandins PGE2 and PGI2, cause 
vasodilation, and PGE2 is also hyperalgesic and a potent inducer of fever [Higgs 
et al., 1984]. COX exists as constitutive and inducible isoforms. Normally,   
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COX-2 is the inducible isoform which elicits an inflammatory reactions in 
peripheral tissues. 
In the CNS, COX-2 plays a major role in a complex and interlocking metabolic 
pathway, converting a structural membrane lipid into a plethora of biologically 
active eicosanoids, with opposite physiological activity. Further, other 
biomolecules such as endocannabinoids or docosanoids are COX-2 substrates, 
expanding the important role of COX-2 in the brain [Strauss, 2008]. In 
physiological condition, significant levels of COX-2 mRNA were found in rodent 
and mammalian brain [Feng et al., 1993; Seibert et al., 1994]. High levels of 
COX-2 mRNA were detected in the hippocampus, piriform cortex, neocortex and 
amigdala, and low levels in striatum, thalamus, cerebellum and hypothalamus 
[Fujimi et al., 2007; Minghetti, 2004] The constitutive COX-2 expression in the 
brain seems to be related to neuronal synaptic plasticity [Minghetti, 2004; 
Kaufmann et al., 1996] and COX-2 inhibitors in rodent Morris Water Maze Test 
have been shown to impair spatial memory [Teather et al., 2002]. Moreover, 
steady-state COX-2 appears to be regulated by normal glutamatergic synaptic 
activity in the adult brain, supporting the role of COX-2 in synaptic plasticity, 
memory consolidation [Strauss, 2008]. In many neurodegenerative diseases, 
COX-2 becomes up-regulated and can promote neuroinflammatory response in 
concert with cytokines, chemokines and other pro-inflammatory molecules 
[Strauss, 2008; Minghetti, 2004]. Glutamatergic excitotoxicity, for instance, 
strongly induces neuronal COX-2 overexpression, as seen in ALS [Strauss, 2008; 
Minghetti, 2004]. In a mouse model of PD, COX-2 overexpression were seen in 
the dopaminergic neurons of the substantia nigra [Teismann et al., 2003] and in 
microglial cells [Knott et al., 2000]. Despite numerous evidence underlies COX-2 
involvement in neurodegenerative diseases, the direct role of COX-2 in brain 
pathology is still controversial and requires further experimental and clinical 
studies to explore, more deeply, neurodegenerative diseases pathology and to 
understand the beneficial or detrimental effect of COX-2 inhibitors in 
neuroinflammation and neurodegeneration [Minghetti, 2004].  
Another important class of mediators and effectors in inflammation are the 
inflammatory cytokines (TNF-α, IL-1, IL-6 and many others). These cytokines are 
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produced by many cell types, most importantly by macrophages or microglia and 
mast cells. They have several roles in the inflammatory response, including 
activation of the endothelium, leukocytes, the induction of the acute-phase 
response and activation of microglial cells during neuroinflammation. 
The potent pro-inflammatory cytokine TNF is a member of the TNF superfamily 
of ligands, many of which promote inflammatory signalling. TNF signalling 
through TNFR1 and TNFR2 can elicit a variety of cellular responses depending 
on many factors, including the metabolic state of the cell and the adaptor proteins 
present in the cell. These differences then influence the activation of a number of 
intracellular signalling pathways including NF-κB, p38, c-jun N-terminal kinase 
(JNK), and the ceramide/sphingomyelinase signalling pathway, resulting in a 
number of responses including inflammation, proliferation, cell migration, 
apoptosis, and necrosis [Eissner et al., 2000; Wajant et al., 2003]. TNF signalling 
has been shown to have several important functions within the CNS including 
injury-mediated microglial and astrocyte activation, and regulation of blood brain 
barrier permeability, febrile responses, glutamatergic transmission, and synaptic 
plasticity and scaling [McCoy and Tansey, 2008; McCoy et al., 2006]. A number 
of pre-clinical and clinical studies in various disease models and in chronic 
neurodegenerative conditions suggest that targeting TNF action in the brain may 
be an attractive disease-modifying strategy to slow progression or attenuate 
severity of the disease [McCoy et al., 2006; Perry et al., 2001]. 
IL-1 was the first interleukin to be identified [Garlanda et al., 2013]. IL-1 is a 
central mediator of innate immunity and inflammation and exerts a number of 
diverse actions in the brain [Patel et al., 2003]. Studies using the IL-1 receptor 
antagonist, which inhibits cell death caused by ischemia or brain injury contribute 
to understand the role of IL-1 in neurodegeneration [Allan et al., 2005; Vezzani et 
al., 2000]. Members of the IL-1 family are expressed at low or undetectable levels 
in healthy brain but their expression become rapidly up-regulated by various 
experimental brain insults including ischaemia, trauma, hypoxia and neurotoxic or 
inflammatory stimuli (LPS) [Lucas et al., 2006; McColl et al., 2007]. Central or 
peripheral administration of IL-1 dramatically increases neuronal death following 
acute brain injury [Yamasaki et al., 1995]. Pro-IL-1β must be cleaved by the 
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enzyme caspase 1, to produce the active form and to allow cellular release 
[Garlanda et al., 2013]. Deletion, inhibition or inactivation of caspase 1 inhibits 
experimentally induced neuronal cell death [Hara et al., 1997]. Increasing 
evidence suggests that IL-1 might also be involved in chronic neurodegenerative 
diseases. In experimental models of AD in mice, β-amyloid-activated microglia 
produce IL-1, which in turn promotes production and deposition of neurotoxic β-
amyloid peptides [Griffin et al., 1998; Ranaivo et al., 2006]. Chronic expression 
of IL-1 in rat brain results in extensive demyelinating lesions, mimicking multiple 
sclerosis, and IL-1RA slows disease progression in experimental autoimmune 
encephalomyelitis, an animal model of multiple sclerosis [Brough et al., 2002; 
Ferrari et al., 2004]. 
IL-6 is an important cytokine originally identified almost 30 years ago as a B-cell 
differentiation factor with novel many critical roles in major physiological 
systems including the nervous system [Erta et al., 2012]. In the brain, IL-6 
influences neurogenesis and it was shown to be involved in multiple physiological 
CNS processes such as neuron homeostasis, astrogliogenesis and neuronal 
differentiation. In many respects, IL-6 behaves in a neurotrophin-like fashion 
[Spooren et al., 2011]. However, the first evidence implicating IL-6 in brain-
related processes originated from its dysregulated expression in several 
neurological disorders such as multiple sclerosis, Alzheimer's disease and 
Parkinson's disease [Spittau et al., 2012; Ramesh et al., 2013]. Its expression is 
affected in several of the main brain diseases, and animal models strongly suggest 
that IL-6 could have a role in the observed neuropathology. In addition, the 
molecular mechanisms underlying IL-6 functions in the brain have only recently 
started to emerge. Further, IL-6 plays a central role in neuroinflammation, which 
can evolve as a beneficial process, aimed at maintaining tissue homeostasis, but 
which can become malignant when exaggerated [Allan and Rothwell, 2001]. In 
this perspective, it is not surprising that 'well-meant' actions of IL-6 are often 
causing harm instead of leading to recovery and therefore it could be a clear target 
of strategic therapies in neurodegenerative diseases in which persistent 
inflammation is the main feature [Erta et al., 2012; Spooren et al., 2011]. 
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It should be noted that it is unclear to what extent the nature of an inflammatory 
trigger dictates the type of mediator induced. In addition, many (but not all) 
mediators not only have direct effects on target tissues but also themselves induce 
the production of additional mediators. It will be important to understand the logic 
underlying this hierarchy of mediators. The effectors of an inflammatory response 
are the tissues and cells, the functional states of which are specifically affected by 
the inflammatory mediators. Responsiveness to certain inflammatory mediators 
(such as TNF-α and IL-1) is almost ubiquitous, although these mediators have 
distinct effects in different tissue and cell types. Although the most obvious effect 
of inflammatory mediators is to induce the formation of an exudate (through their 
effects on the vasculature and on leukocyte migration), many inflammatory 
mediators have other, equally important, effects on neuroendocrine and metabolic 
functions and on the maintenance of tissue homeostasis in general [Turnbull and 
Rivier, 1999]. These functions of inflammatory mediators reflect a more general 
role for inflammation in the control of tissue homeostasis and in adaptation to 
noxious conditions. 
 
1.3 TLRs in the brain: focus on TLR4 
TLRs are expressed in a wide variety of immune, as well as on non-immune cells. 
Whereas dendritic cells (DCs), neutrophils or macrophages express an almost 
complete panel of the different TLRs, other cells only express a restricted 
repertoire. Given the crucial role TLRs, but also other innate immune receptors, 
play in the initiation of innate as well as adaptive immune responses, their 
involvement in the pathogenesis of chronic inflammatory or autoimmune diseases 
is not surprising. In fact, functionally active TLRs were found to be expressed in 
different cells of the CNS, and interestingly also seem to be involved in 
neurodegenerative diseases [Kielan, 2006; Konatet al., 2006].To date, there is 
accumulating evidence that TLR4 and TLR2 activation play a crucial role in the 
development and progression of a number of neurodegenerative diseases 
[Schröder and Schumann, 2005; Ziegler et al., 2011]. 
TLR4 was first identified, in 1998, as the signalling receptor for LPS or endotoxin 
from the outer membrane of Gram-negative bacteria [Poltorak et al., 1998]. In 
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CNS, constitutive expression of TLR4 transcripts has been described in distinct 
anatomical areas of the brain such as circumventricular organs, choroid plexus and 
leptomeninges [Lacroix et al., 1998; Laflamme and Rivest, 2001]. TLR4 has also 
been reported to be expressed in microglia and astrocytes [Lehnardt et al., 2003; 
Lehnardt et al., 2002; Gorina et al., 2011].In addition, the expression of TLR4 has 
recently been documented, despite controversial, in mammalian neurons and 
appears to be implicated in several processes such as neurogenesis and brain 
development [Wadachi and Hargreaves, 2006; Rolls et al., 2007]. TLRs have been 
shown to be implicated in several CNS diseases, and accumulating evidence 
demonstrates that TLR4 contributes to neuronal death, blood brain barrier 
damage, cerebral edema, and inflammatory responses in the brain injury induced 
by ischemia [Caso et al., 2007; Hua et al., 2007]. TLR4-mediated activation of 
NF-κB signalling plays a vital role in the initiation of cerebral inflammation in 
CNS diseases [Hua et al., 2007; Kerfoot et al., 2004], leading to the transcription 
of many pro-inflammatory genes encoding cytokines, chemokines, and enzymes 
such as COX-2 and MMP-9, that are involved in the development of secondary 
brain injury following traumatic brain injury (TBI) [Wang et al., 2009; Lucas et 
al., 2006]. The upregulation of cytokines and chemokines could activate 
microglia, thus initiating infiltration of inflammatory cells into the brain which 
may cause neuronal loss [Allan and Rothwell, 2001; Morganti-Kossmann et al., 
2002]. Considering the critical role of TLR4 in neuroinflammation and brain 
injury, recent insights into the role and activation mechanisms of TLR4 in the 
brain should be better characterized, not only in pathological events but also in 
physiological conditions, as well as the therapeutic benefit that could derive from 
TLR4 modulation.  
 
1.3.1 LPS and TLR4 pathways 
The constitutive expression of TLR4 may explain the innate immune response in 
the brain, which originates from the structures devoid of the blood–brain barrier in 
the presence of circulating LPS, thus suggesting a role for TLR4 acting as a sensor 
for engaging the cerebral innate immune response in the case of invasion during 
systemic bacterial infections, which may have detrimental consequences for the 
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neuronal structures [Laflamme and Rivest, 2001]. In this respect, in an in vivo 
model of neurodegeneration, LPS administration was reported to be able to 
stimulate innate immunity, causing extensive neuronal and axonal loss in the 
cortex. In contrast, animals bearing a loss-of-function mutation in the TLR4 gene 
are resistant to neuronal injury, thus demonstrating a mechanistic link among 
innate immunity, TLRs, and neurodegeneration [Lehnardt et al., 2003]. 
In the host system, LPS capture is facilitated by the LPS binding protein (LBP) 
which transfers it to the receptor complex composed of CD14, MD-2 (or LY96) 
and TLR4. Upon LPS binding, TLR4 recruits, through its short intracellular TIR 
domain, adaptor molecules and kinases, thus initiating a downstream signalling 
cascade that culminates in the secretion of pro-inflammatory cytokines and 
chemokines [Takeda and Akira,2005;Takeuchi and Akira, 2002]. Activation of 
TLR4 by LPS induces two signalling pathways known as the myeloid 
differentiation primary response gene 88 (MyD88) dependent and independent 
pathways (Fig.3) [Akira et al., 2006]. The MyD88 dependent pathway in TLR4 
signalling requires the adaptor proteins TIRAP (TIR domain containing adaptor 
protein) and MyD88 to initiate a downstream cascade leading to nuclear 
translocation of the NF-κB and mitogen associated protein (MAP) kinase 
signalling pathways (such as ERK-CREB, JNK-AP1and p38 pathways), resulting 
in the production of pro-inflammatory cytokines [Kargan and Medzhitov, 2006]. 
This leads to the rapid expression of inducible nitric oxide synthase (iNOS) and a 
wide variety of pro-inflammatory cytokines, chemokines and their receptors, 
including TNF-α, IL-1α, IL-1β, IL-1ra, IL-6, IL-8, IL-10, IL-12p40, IL-23, 
macrophage inflammatory protein (MIP)-1α, and MIP-1β [Lee and Kim, 2007]. 
These factors initiate the inflammatory response, increase vascular permeability, 
direct DC and macrophage migration from the periphery to the central lymphoid 
organs, activate glial cells and regulate various aspects of adaptive immunity 
development. On the other hand, the independent signalling pathway is controlled 
by the adaptors TICAM (Toll-like receptor adaptor molecule) 1 or TRIF (TIR-
domain-containing adaptor inducing interferon-β) and TICAM 2 or TRAM 
(TRIF-related adaptor molecule), which activate the transcription factor IRF3 
(IFN regulatory factor 3) and the production of IFN-β and chemokine RANTES 
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(regulated on activation normal T cell expressed and secreted) [Yamamoto et al., 
2003a].TLR4 engagement leads to the production of neurotoxic molecules such as 
pro-inflammatory cytokines, NO, ROS and peroxynitrite [Xie et al., 2002]. 
 
 
 
Figure 3 :Overview of LPS/TLR4 signalling pathway. Stimulation of TLR4 by LPS 
involves the participation of several molecules (LBP, CD14 and MD-2). Activation of TLR4 
induces two downstream signalling pathways. First, the MyD88-dependent pathway is 
initiated by recruitment of TIRAP and MyD88 to the TLR4 complex which leads to early-
phase activation of NF-κB and subsequent induction of the expression of NF-κB-controlled 
genes including pro-inflammatory cytokines (TNF-α). The MyD88-dependent pathway can 
also activate JNK, leading to transcription of several genes including TNF-α, via activation of 
AP-1. Second, the MyD88-independent pathway is initiated by recruitment of TRAM and 
TRIF to the TLR4 complex, followed by late activation of NF-κB complex and activation of 
IRF3 which leads to the transcription of IFN-β as well as other interferon-induced genes. 
(from Lehnardt et al., 2002) 
 
Moreover, LPS-activated microglia produce a large amount of glutamate, an 
important neurotransmitter which in some circumstances acts as a potent 
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neurotoxin [Takeuchi et al., 2006]. LPS challenge may also activate TLR4 on the 
microglia surface, leading to oligodendrocyte injury [Lehnardt et al., 2002]. 
Recently, CNS-relevant in vitro and in vivo studies have highlighted the function 
of suppressor of cytokine signalling (SOCS) proteins under various 
neuroinflammatory or neuropathological conditions. SOCS1 and SOCS3 have 
been described as having a short half-life (1–2 h) and their expression levels are 
reported to increase rapidly following macrophage exposure to inflammatory 
cytokines and TLR ligands. Expression of SOCS1 and SOCS3 is regulated 
primarily by activation of STAT1 and STAT3, respectively, although their 
expression can be mediated through other signalling cascades, including MAPK 
and NF-κB pathways [Wang and Campbell, 2002; Blach-Olszewska and Leszek, 
2007]. Moreover, SOCSs not only influence cytokine and growth hormone 
signalling, but also the signalling pathway initiated by the reaction of a TLR with 
PAMP or an endogenous molecule. SOCS-1 negatively regulates TLR signalling 
by mediating the degradation of the adapter protein Mal. This protein is involved 
in signalling via TLR2 and TLR4. Because of their obvious biological importance, 
the SOCS proteins have been the subject of intense investigation, including the 
development of strategies to utilize these proteins to control cytokine induced 
JAK/STAT signal transduction for therapeutic purposes [Blach-Olszewska and 
Leszek, 2007]. Although it is undisputed that TLR4 recognizes LPS, an important 
role has been attributed to molecules of host origin that have lately emerged as 
potential endogenous ligands of TLR4, including different components of the 
extracellular matrix, intracellular proteins, or modified lipids or lipoproteins 
(Table 1). Interestingly, many of them are able to activate both TLR4 and TLR2 
without having any substantial structural similarity to their natural ligands 
(endotoxin or lipopeptides, respectively) [Oblak and Jerala, 2011]. However, as a 
potent immune activator LPS can activate TLR4 at smaller concentrations than 
other activators (e.g., heat shock proteins, fibrinonectins, oligosaccharides, 
heparin sulphate, and fibrinogen) [60]. The emerging evidence is that many of 
these molecules may be more accurately described as PAMP-binding molecules or 
PAMP sensitizing molecules, rather than genuine ligands of TLR2 or TLR4. 
Consequently, these molecules may serve a beneficial purpose initially by 
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enhancing the sensitivity of compromised tissues to a potential microbial 
challenge, or, alternatively, it is proposed that they may also play a role in the 
maintenance of chronic inflammatory diseases [Erridge, 2010]. Paradoxically, 
TLR activation by endogenous ligands following ischemia worsens stroke 
damage, therefore these molecules, recently termed “alarmins”, have been 
suggested to serve as mediators of inflammation that may be expressed or released 
in response to tissue damage and, therefore, have also been described as DAMPs 
[Bianchi, 2007]. In the brain the following molecules have been reported as 
DAMPs: heat shock proteins (HSPs), β-amyloid (Aβ), hyaluronan, heparin 
sulphate, DNA or RNA immune complex, oxidized low-density lipoproteins 
(oxLDL), and others, all able to stimulate TLRs [Marsh et al., 2009; Rivest, 2009; 
Yanai et al., 2009; Stewart et al., 2010; Zhang et al., 2010]. Among DAMPs, 
high-mobility group box-1 (HMGB1), a non-histone nuclear protein, has been 
reported to exert its biological effects through the activation of signalling 
pathways coupled to TLRs, including TLR4 and RAGE, both of which are 
involved in inflammatory responses [Park et al., 2004; Yang et al., 2010; Rauvala 
and Rouhiainen, 2010]. Recent studies show that elevated brain levels of HMGB1 
induce memory abnormalities which may be mediated by either TLR4, or RAGE. 
This mechanism may contribute to memory deficits under various neurological 
and psychiatric conditions associated with increased HMGB1 levels, such as 
epilepsy, Alzheimer's disease and stroke [Mazarati et al., 2011]. 
 
1.4 Microglia: the key regulator of brain microenvironment 
Microglia are bone marrow-derived cells of the brain displaying multiple roles in 
regulatory processes such as maintaining homeostasis and repairing from injury. 
This heterogeneous group of monocyte-derived cells orchestrate innate immune 
response in the brain and show different phenotypes depending on functional 
connotation [Kettenmann et al., 2011]. In 1932, Pio del Rio Hortega provided an 
early description of microglia. He postulated that morphological classification of 
microglia fell into three different phenotypes: ramified, intermediate forms and 
amoeboid [Tremblay et al., 2011]. Scientists have shown that during postnatal 
development, progenitors from mesodermal/mesenchymal origin migrate through 
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the peripheral blood into the brain where they become tissue specific 
macrophages. The colonization of the brain by microglia occurs parallel to the 
vascularization of the CNS. Microglial cells initially show amoeboid shape and 
once migrated into the brain, they transform into a branched, ramified 
morphological phenotype termed “resting” microglia [Kettenmann et al., 2011; 
Tremblay et al., 2011; Ginhoux, 2013]. The switch from an amoeboid state to the 
resting state seems to be linked to the release of molecules such as purines (e.g., 
ATP or adenosine), cytokines from astrocytes [transforming growth factor-β 
(TGF-β), macrophage colony-stimulating factor (M-CSF) and 
granulocyte/macrophage colony-stimulating factor (GM-CSF)] and chloride 
channels [Kettenmann et al., 2011; Dheen et al., 2007]. Microglia present 
different inwardly rectifying K
+
 channels, receptors for purines (e.g., P2X7R) and 
neurotransmitters (GABA, NMDA, D2 etc.) [Kettenmann et al., 2011]. The 
resting microglial cells tight regulate CNS microenvironment, surveying brain 
parenchyma via dynamic movement of the ramified processes. They control the 
extracellular environment and perceive even small changes in the ionic 
composition of the extracellular fluid surrounding neurons, without disturbing the 
fragile neuronal circuitry [Kettenmann et al., 2011; Tremblay et al., 2011]. To 
protect vulnerable nervous tissue from a potential harmful immune response, the 
brain is under a tight regulated control termed “immune-privilege” and microglial 
cells participate in this complex regulation [Carson et al., 2006].  
Microglial immune function is regulated by two different types of signals known 
as “Off” and “On” signals. Neuronal Off signals are found in healthy neurons and 
can maintain microglia in a resting state by secreting neurotransmitters (e.g., 
GABA), the immunoglobulin CD200, the chemokine CX3CL1 and neurotrophins, 
such as neuronal growth factor (NGF), brain derived neutrophic factor (BDNF), 
neurotrophin-3 (NT3) and cytokines with neurotrophic activity. By contrast, On 
signals start to be produced when a defined microglial activation is required. In 
response to impaired neurons On signals are released. These signals include 
neurotransmitters (e.g., ATP, UTP and glutamate), matrix metalloproteinases 
(MMPs), chemokines (e.g., CCL21, CXCL10), and membrane On signals such as 
TREM2 ligand in the membrane of apoptotic neurons to drive microglia 
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phagocytosis [Biber et al., 2007; Ransohoff and Perry, 2009]. This represent the 
“proof of principle” of a bidirectional microglia-neuron communication in the 
brain and provides novel insights in understanding microglial function in both the 
healthy and diseased brain [Eyo and Wu, 2013].  
1.4.1 “Activation” of microglia during neuroinflammation 
During alterations in brain activity or invading microbes, microglia can be 
activated to perform the first line of defence. They initiate rapid changes in gene 
expression, cell shape and functional behaviour becoming “activated” (Fig.4) 
[Kettenmann et al., 2011; Saijo and Glass, 2011]. Activated microglia moved to 
the lesion following chemotactic gradients by reverting their resting state to an 
amoeboid state. They undergo complex changes in intracellular enzymes activity 
and start to release a plethora of pro-inflammatory and immunoregulatory factors 
such as cytokines, reactive nitrogen species, chemokines, neurotrophic factors and 
chemoattractive factors [Kettenmann et al., 2011; Saijo and Glass, 2011; 
Hoogland et al., 2015]. Microglia physically associate with damaged neurons, 
presenting the antigen to T cell and lead to neuronal apoptosis. In acute 
pathological condition microglia are not inevitably neurotoxic. In fact, it has been 
demonstrated that microglial neurotoxicity can occur after excessive, chronic, 
uncontrolled stimulation of microglia or when microglia function is impaired 
[Hoogland et al., 2015¸ Lull and Block, 2010]. One physiological event that could 
induce microglial exaggerated response and neurotoxicity is normal aging. 
Healthy adult brain shows an higher microglial expression of the major 
histocompatibility complex(MHC) class II and IL-6, also accompanied with an 
increased oxidative stress, decreased IL-10 and age-related decline in cognitive 
and motor function [Norden and Godbout, 2013; Von Bernhardi et al., 2015].This 
evidence could explain why in aged individuals a systemic infection can induce an 
exaggerated inflammatory response in the brain due to an over-activation of 
microglia and neuronal cell damages. Finally, microglia, in a close crosstalk with 
astrocytes, neurons and other brain cells, play crucial functions as the scavenger 
system of the CNS, providing beneficial functions as tissue repair in the CNS. 
However, chronic, dysregulated activation of microglia appears to lead to 
deleterious effects inducing malfunction and damage of brain cells. What drives 
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this dysregulation is not fully understood, but age-related impairment of 
regulatory mechanisms represent a promising hypothesis for understanding 
cytotoxic activation in aged individuals [Von Bernhardi et al., 2015]. 
 
Figure 4. Microglial activation states. In the healthy CNS, microglia survey their immediate 
environment, and in this “resting state”, do not express inflammatory mediators. However, after 
exposure to a number of chemical signals from damaged neurons, microglia respond rapidly and 
physically migrate to the site of injury. Responding microglia may then adopt a pattern of behavior 
similar to pro-inflammatory macrophages (shown in red), as they release molecules intended to 
protect against pathogens, including neurotoxic cytokines, reactive oxygen species (ROS), and 
small molecules, such as quinolinic acid, that promote excitotoxicity. The release of cytokines and 
chemokines can lead to the recruitment of additional inflammatory cells from adjacent blood 
vessels, and may also engage astrocytes in the pro-inflammatory response. Alternatively, activated 
microglia may exhibit behaviors associated with anti-inflammatory macrophages (shown in green), 
secreting molecules that promote tissue repair, and internalizing cellular debris including 
aggregated, misfolded proteins such as β-amyloid, through phagocytosis. Whether two distinct 
populations of microglia exist that are committed to either of these response patterns, or all 
microglia can be induced to exhibit either response behavior when exposed to the correct 
combination of signals, remains to be determined (from Garden and La Spada, 2012). 
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Nonetheless, despite the undeniable potential of activated microglia to become 
deleterious, microglia have a profound immune-modulatory and reparative 
potential in the CNS. Thus, instead of abolishing microglia activation as it is most 
often proposed, strategies to potentiate those beneficial functions while inhibiting 
cytotoxic activation should be developed. Such strategy may well constitute the 
way to treat neurodegenerative disorders, but demands a better understanding of 
the protective and modulatory pathways of immune activation. Additional 
research is needed for the identification of new pathways that may decrease the 
impact of microglial cell dysfunction, in order of breaking the vicious circle 
leading to neurotoxicity. In that perspective, multi-target pharmacological 
approaches, like natural compounds and their phytocomplexes, aimed to 
reestablish normal regulation of microglia could prove highly effective, especially 
as preventive treatments. Furthermore, non-pharmacological strategies, like 
exercise, life style changes and dietary restriction could promote a healthy aging 
through their effects on promoting microglial physiological functions, while 
reducing inflammation and ROS production. 
 
1.5 Astrocytes in neurodegeneration 
Astrocytes are characteristic star-shaped glial cells located in CNS and enteric 
nervous system and play a critical role in the viability and function of the CNS, 
including biochemical support of endothelial cells that form the blood–brain 
barrier, provision of nutrients to the nervous tissue and involved in the 
maintenance of extracellular ion balance and in the repair and scarring process of 
the brain and spinal cord following traumatic injuries [Sofroniew and Vinters, 
2010]. Astrocytes become reactive in response to virtually all pathological 
conditions in the CNS, both following acute injuries (stroke, trauma) and during 
progressive diseases [Sofroniew, 2005]. Thus, it is not surprising that these 
multifunctional cells have been implicated in the onset and progression of several 
neurodegenerative diseases like Parkinson (PD), Alzheimer(AD), Amyotrophic 
lateral sclerosis (ALS); and multiple sclerosis (MS) among others [Clement et al., 
2003; Wisniewski and Wegiel, 1991; Haughey and Mattson, 2003; Forman et al., 
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2005; Shin et al., 2005; Forno et al., 1992; Teismann and Schulz, 2004; Heales et 
al., 2004].  
 
 
Figure 5. Potential astrocyte dysfunction in neurodegenerative diseases. (1) Impairment of 
glutamate transporters, through reduced expression, aberrant RNA synthesis or altered function, 
results in increased synaptic glutamate and excitotoxicity [Heales et al., 2004]. (2) Amyloid-β 
could potentially increase the amount of ATP released by astrocytes, as well as interacting with 
gap junctions to alter calcium signalling and glial communication [Haughey and Mattson, 2003]. 
(3) Upregulation of glial fibrillary acidic protein is a consistent pathological feature in 
neurodegenerative diseases, although the significance of this observation is not completely 
understood [Luo et al., 2010; Brenner et al., 2001]. (4) Nitric oxide stimulates the release of 
glutathione from astrocytes to neurons, thereby increasing neuronal antioxidant reserves and 
limiting oxidative damage to neuronal mitochondria [Sofroniew, 2005]. (5) Mutations in glial 
fibrillary acidic protein associated with Alexander disease result in the development of Rosenthal 
fibers, and lead to disordered intermediate neurofilament organization [Brenner et al., 2001]. (6) 
Neurons surrounded by mutant astrocytes develop protein aggregates and axonal pathology, and 
are more susceptible to cell death in several neurodegenerative disease models, including 
amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's disease [Wakabayashi et al.,  
2000; Teismann and Schulz, 2004; Watanabe et al., 2001]. (7) Mutant huntingtin expressed in 
astrocytes forms intranuclear aggregates and also influences neuronal cell death in vitro [Shin et 
al., 2005]. (8) Amyloid-β42-positive material is seen within activated astrocytes in the tissues of 
individuals with Alzheimer's disease, and is abundant in regions with the most active Alzheimer's 
disease pathology [Haughey and Mattson, 2003]. (9) Accumulation of mutant superoxide 
dismutase 1 is also observed in astrocytes [Clement et al., 2003]. (10) Finally, communication 
between abnormal or injured astrocytes might affect the biology and function of surrounding 
normal astrocytes, through either hemichannels or soluble mediators [Sofroniew et al., 2005]. 
Abbreviations: Aβ, amyloid-β; GFAP, glial fibrillary acidic protein; GSH, glutathione (from 
Maragakis and Rothstein, 2006). 
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The involvement of astrocytes in the neuropathology of these diseases is likely a 
consequence of both the loss of normal homeostatic functions and gain of toxic 
functions [Sofroniew and Vinters, 2010]. Intracellular aggregates in astrocytes are 
a common feature of various neurodegenerative diseases, and these aggregates 
perturb normal astrocytic functions in ways that can be harmful to neuronal 
viability [Wakabayashi et al., 2000].It has been very difficult to distinguish the 
contribution of astrocytes from that of microglia because they usually become 
reactive in concert and both are involved in neuroinflammation. However, they 
have quite different functions in the brain in normal conditions; therefore, they 
may also play different roles during neurodegenerative diseases [Sofroniew and 
Vinters, 2010].In response to insults or injuries in the CNS, astrocytes respond 
through the so called “reactive astrogliosis”, which consist of a graded response 
that encompasses a spectrum of changes that range from hypertrophy to 
proliferation and migration [Sofroniew and Vinters, 2010].Astrocyte hallmark of 
reactivity is a strong Glial fibrillary acidic protein(GFAP) expression and 
upregulation of vimentin and nestin. Another cardinal feature of astrocyte 
reactivity is hypertrophy, which was reported by early neuropathologists. Reactive 
astrocytes display an enlarged cell body and processes [Sofroniew, 2005; Brenner 
et al., 2001; Sofroniew and Vinters, 2010; Sun et al., 2010]. In addition, astrocyte 
arborization is reorganized with reactivity: the number of primary processes 
changes or they polarize toward the site of injury or toward amyloid plaques in 
AD (Fig.5) [Sun et al., 2010; Bardehle et al., 2013].The nature and extent of the 
astrocytic response is determined by the context in which it occurs and by the 
duration and nature of the instigating stimulus. For example, LPS, stroke, and 
other insults can induce very different kinds of reactive gliosis [Zamanian et al., 
2012; Gorina et al., 2011]. Reactive astrocytes can release a wide variety of 
extracellular molecules, including inflammatory modulators, chemokines and 
cytokines, and various neurotrophic factors. These factors can be either 
neuroprotective (e.g., cytokines, such as IL-6 in some condition and TGF-β) or 
neurotoxic (such as IL-1β and TNF-α) [Sofroniew et al., 2010].In light of their 
many actions on neurons, strategies targeting reactive astrocytes may effectively 
sustain neuronal function and hence survival during neurodegenerative diseases. 
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However, given the complex changes that occur in reactive astrocytes during 
neurodegenerative diseases, complete ablation of astrocyte reactivity may be 
counterproductive because these cells also display beneficial adaptative changes 
during disease. Identifying the complex interplay between shared intracellular 
pathways mediating reactivity and disease specific signals may enable the design 
of selective therapeutic cocktails to engage reactive astrocytes in protective 
actions. Huge progress has been made recently as a result of the heightened 
interest in glial cells, and the development of innovative and cell type-specific 
approaches. However, these cells remain enigmatic, and many aspects of their 
physiology need to be clarified. Although the molecular pathways leading to 
astrocyte reactivity during ND have been described, it is crucial to elucidate what 
disease-, region- and environmental-specific mechanisms control the functional 
outcomes associated with astrocyte reactivity. In any case, considering reactive 
astrocytes as key partners in neuronal dialog during neurodegenerative diseases 
opens new avenues for neuroscience and biomedical research [Dantzer et al., 
2008]. 
 
1.6 Oligodendrocytes and neurodegeneration 
Nowadays, an important component of neuroglia, oligodendrocyte, has received 
more attention in the field of neurodegenerative disease research. Traditionally, 
oligodendrocytes were recognized as myelin sheath producers by which saltatory 
conduction of action potential is guaranteed. However, emerging evidence has 
suggested that oligodendrocytes exert supportive functions for neurons and their 
axons in a myelin sheath-independent manner [Bradl and Lassmann, 2010], and 
thus, impairment in oligodendrocyte functions has been reported in several 
neurodegenerative diseases, such as ALS and AD. These diseases are considered 
to be not associated with myelin-forming cells [Lee et al., 2012; Roth et al., 2005; 
Nonneman et al., 2014]. The interesting observations prompt us to rethink our 
traditional views on oligodendrocytes and their possible roles in the pathogenesis 
of neurodegenerative disorders. A clear experimental evidence, showing the 
supportive function of oligodendrocytes in axon health independent of myelin 
sheath, came from the study using 2',3′-cyclic nucleotide 3′ phosphodiesterase 
 29 
 
(CNP1) mutant mice in which the CNP1 gene was disrupted by Cre insertion 
[Lappe-Siefke et al., 2003]. The overall pattern of myelin proteins, amount and 
ultrastructure of the central myelin were almost the same as littermate controls in 
the absence of CNP1. However, by four months of age, progressive motor deficits 
in motor performance, axon pathology and reactive gliosis became more visible. 
In this mutant mouse line, the supportive role of oligodendrocytes in axon 
integrity was completely uncoupled from its role of myelin sheath maintenance, 
suggesting that dysfunction of oligodendrocytes is sufficient to cause secondary 
axonal neurodegeneration. Further evidence supports this hypothesis. For 
example, absence of functional peroxisomes in oligodendrocytes resulted from 
inactivation of perioxisomal biogenesis factor-5 (PEX5), a factor known to be 
essential for peroxisomal protein import, caused wide-spread axonal degeneration, 
progressive demyelination and pronounced neuroinflammation [Kassmann et al., 
2007]. These data highlight the importance of oligodendrocytes on 
neuroprotection. More recently, two very interesting studies revealed that 
metabolite coupling between oligodendrocytes and neurons is important for 
neuronal survival and its deregulation contributes to neurodegeneration. In these 
studies, cytochrome c oxidase assembly protein 10 (Cox10) gene, a haem A 
farnesyl transferase essential for assembly of mitochondria complex IV, and 
monocarboxylate transporter 1 (MCT1) were depleted specifically in 
oligodendrocytes [Fünfshilling et al., 2012; Lee et al., 2012]. More importantly, 
Lee and colleagues found that monocarboxylate transporter 1 (MCT1) was highly 
enriched in oligodendrocytes and its levels were reduced in ALS mouse models 
and neural samples of ALS patients, suggesting the involvement of 
oligodendrocytes in ALS pathogenesis [Lee et al., 2012]. 
In summary, oligodendrocytes are multi-functional glial cells in the CNS and they 
actively play important roles under both physiologic and pathological conditions. 
Their dysfunction can contribute to several neurodegenerative diseases including 
ALS, MSA and AD, although the precise molecular and cellular mechanisms are 
still unknown. More detailed investigations will significantly broaden our 
understanding of disease pathogenesis and oligodendrocyte pathophysiology and 
could help to identify new therapeutic targets in neurodegenerative diseases. 
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1.7 Neuroinflammatory basis of neurodegenerative diseases 
Nowadays, neurodegenerative diseases are chronic and incurable conditions 
whose disabling effects may continue for years or even decades, representing an 
enormous disease load, regarding human suffering and economic cost. The 
disproportionate impact on countries with longer life expectancies make 
neurodegenerative diseases the fourth highest source of overall disease burden in 
the high-income countries. According to the World Health Organization, 37 
million people currently have dementia worldwide, and about 50% of them are 
being affected by AD and this number is expected to grow up to 115.4 million 
people by 2050 [Brown et al., 2005]. 
Neurodegenerative diseases are characterized by chronic and progressive 
degeneration of selective neuronal populations. Inflammation is a common 
hallmark in many neurodegenerative diseases, including Alzheimer's disease, 
Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis. [Glass et 
al., 2010]. Extensive research so far has identified many molecular and cellular 
factors that contribute to the initiation and progression of inflammatory response 
in neurodegenerative diseases. Among them, glial activation, mainly astrocytes 
and microglia, takes an important place in the pathology of neurodegenerative 
disorders. This may be due to their widespread involvement in the maintenance 
and regulation of brain homeostasis [Glass et al., 2010; Mena and Garcìa de 
Yébenes, 2008].Sustained inflammation resulting in tissue pathology implies 
persistence of an inflammatory stimulus or a failure in normal resolution 
mechanisms. A persistent stimulus may result from environmental factors or the 
formation of endogenous factors (e.g., protein aggregates) that are perceived by 
the immune system as “stranger” or “danger” signals. Inflammatory responses that 
establish feed-forward loops may overwhelm normal resolution mechanisms. 
Although some inflammatory stimuli induce beneficial effects (e.g., phagocytosis 
of debris and apoptotic cells), and inflammation is linked to tissue repair 
processes, uncontrolled inflammation may result in production of neurotoxic 
factors that amplify underlying disease states [Glass et al., 2010]. 
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1.7.1 Alzheimer's Disease 
Initially described almost 100 years ago by Alois Alzheimer, AD is one of the 
most common age-related neurodegenerative diseases, affecting approximately 
30% of people older than 70 years worldwide. The symptoms of AD are 
characterized by loss of memory, progressive impairment of cognition, and 
various behavioral and neuropsychiatric disturbances. The pathological hallmarks 
of AD in the brain include extracellular amyloid plaques comprising aggregated, 
cleaved products of the amyloid precursor protein (APP) and intracellular 
neurofibrillary tangles (NFTs) generated by hyperphosphorylated forms of the 
microtubule-binding protein tau [Glass et al., 2010; Parihar and Hemnani, 2004]. 
The role of neuroinflammation in AD has been assumed to be merely a response 
to pathophysiological events. However, novel insights from preclinical and 
clinical studies have determined that immune system-mediated actions, in fact, 
contribute to and drive AD pathogenesis [Heppner et al., 2015]. Inflammatory 
response in AD includes activation of microglial cells, from ramified (resting) to 
amoeboid (active), and astrogliosis (increase in the number, size, and motility of 
astrocytes) surrounding the senile plaques. Moreover, activated microglia releases 
pro-inflammatory mediators, including COX-2, TNF-α, IL-1β, IL-6 and MCP-1 
[Glass et al., 2010; Heppner et al., 2015]. The latter is known to induce astrocytes 
chemotaxis and recruitment around senile plaques [Wyss-Corayet al., 2003]. In 
addition, elevated levels of chemokines and cytokines and their receptors, 
including IL-1α, CXCR2, CCR3, CCR5, and TGF-β, have been reported in post-
mortem AD brains [Khandelwal et al., 2011]. 
 
1.7.2 Parkinson’s disease  
Parkinson's disease is the second most common neurodegenerative disease after 
AD, characterized by motor dysfunction (bradykinesia, tremor, rigidity, and 
postural instability) and non-motor-related symptoms (olfactory deficits, 
autonomic dysfunction, depression, cognitive deficits, and sleep disorders). 
Pathological hallmarks in PD are accumulation and aggregation of misfolded α-
synuclein in the so called Lewy bodies and Lewy neuritis, and the loss of 
dopaminergic neurons in the pars compacta of substantia nigra of the midbrain 
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and in other brain regions primarily involved in the control of motor functions 
[Braak et al., 2003]. Dopaminergic neurons are very sensitive to the surrounding 
environment and inflammatory processes can easily cause them degeneration. In 
fact, activation of microglia seems to precedes DA neuronal cell loss and neurons 
undergoing degeneration may be phagocytosed prematurely by phagocytic 
microglia (Fig.6) [Marinova-Mutafchieva et al., 2009]. An increase in astroglial 
cells in postmortem tissue from the brains of PD patients and an increased number 
of dystrophic astrocytes have also been reported [Braak et al., 2007]. Although 
these inflammatory components are not specific for PD, they might provide useful 
biomarkers for monitoring disease progression. 
 
Figure 6. Inflammation in Parkinson's Disease. Prominent neuropathological 
hallmarks of Parkinson's disease  are the loss of dopaminergic neurons in the 
substantia nigra of the midbrain and the presence of intracellular inclusions 
containing aggregates of the α-synuclein protein, called Lewy bodies. Besides 
forming Lewy bodies, aggregates of α-synuclein form intermediate-state oligomers 
that when released from neurons activate microglia through Toll-like receptor 
(TLR)-independent mechanisms. This leads to activation of NF-κB and production 
of reactive oxygen species (ROS) and pro-inflammatory mediators. These factors act 
directly on dopaminergic neurons of the substantia nigra, which are the principal 
(although not the only) neurons that die in PD. These factors also activate microglia, 
which amplify the inflammatory response in a positive feedback loop, leading to 
further activation of microglia. Products derived from microglia and astrocytes act in 
a combinatorial manner to promote neurotoxicity (from Glass et al., 2010) 
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1.7.3 Multiple sclerosis 
Multiple sclerosis is a chronic autoimmune inflammatory neurodegenerating 
disorder affecting movement, sensation, and body functions with considerable 
social impact and economic consequences. Onset of MS typically occurs during 
adulthood and patients experience an early loss in productivity, making MS the 
major cause of serious physical disability in young adult, especially women 
[Compston and Coles, 2008; Dendrou et al., 2015].The main pathological features 
of MS are inflammatory infiltrates, destruction of the myelin sheath and 
oligodendrocytes, axonal and neuronal damage as well as glia proliferation 
[Brück, 2005]. These hallmarks vary over time both quantitatively and 
qualitatively between MS subclinical types and among individuals with the same 
form [Lassmann, 2014]. MS lesions are characterized by infiltration of 
lymphocytes and antibody-producing plasma cells into the perivascular region of 
the brain and spinal cord white matter, an increase in microglia and astrocytes, 
and demyelination [Compston and Coles, 2008; Brück, 2005]. The deposition of 
antibodies and complement around demyelinated lesions and axonal degeneration 
in the progression phase of MS have also been observed [Brück, 2005;Lassmann, 
2014]. When damage and the ensuing inflammatory response are transient, 
remyelination of nerves can take place as part of normal repair. However, in the 
presence of chronic inflammation, such as in MS, remyelination is severely 
impaired and leads to neuron degeneration. 
 
As mentioned above, neurodegenerative diseases can be distinguished by disease-
specific mechanism for induction of inflammatory response. However, once 
inducers are generated, effector mechanisms that lead to amplification of 
inflammatory responses, neurotoxicity, and neuronal death are convergent. In fact, 
activation of innate immune cells in the CNS, such as microglia and astrocytes, is 
one of the universal components of neuroinflammation. In particular, activation of 
TLRs and other pattern recognition receptors expressed on microglia initiate the 
inflammatory responses that are further amplified by astrocytes. This, lead to 
signal transduction pathways downstream which activate transcription factors 
such as NF-κb and AP-1 and the production of quite the same amplifiers and 
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effector molecules, such as cytokines , ROS, and NO found in all the 
neurodegenerative diseases discussed before [Glass et al., 2010; Gorina et al., 
2011].  
It is likely that sustained inflammatory responses that contribute to 
neurodegeneration are driven, at least in part, by positive feedback loops. 
Crosstalk between microglia and astrocytes is predicted to lead to amplification of 
inflammation and release of ATP by necrotic neurons that would be expected to 
activate microglia in each of the disease. Such feedback loops could, in principle, 
become independent of the original inducing molecules that are required to initiate 
inflammatory responses. In addition, inflammation may itself influence the 
production of disease-specific inducers. It is important to understand how 
activated immune cells affects specific types of neurons.  For example, many of 
the same cytokines are suggested to play pathological roles in AD, PD, and ALS, 
but the patterns of neuronal loss are distinct. It will therefore be important to 
determine whether this difference reflects different sensitivities of specific 
neurons to generic neurotoxic factors or the production of neurotoxic factors with 
neuron-specific activities [Glass et al., 2010]. 
In this context, therapeutic approaches logically would aim to modulate the 
sensor/transducer/effector functions of the innate immune system. In terms of 
timing, efficacy, and safety targeting inflammatory pathways might be more 
effective in preventing disease progression than in reversing existing pathology. 
To be clinically effective, anti-inflammatory therapies will have to gain access to 
the CNS and target specific cells and pathways that are quantitatively important in 
disease pathogenesis in humans. As AD, PD, and ALS are chronic degenerative 
diseases, it is likely that their prevention and treatment will require long-term 
therapy, imposing a corresponding requirement for a high level of safety. Among 
multi-targeting therapies, phytocomplexes can successfully and rationally being 
used together with both already available drugs and those in process of 
development. Phytocomplexes contain combinations of bioactive molecules and 
thus provide synergistic effects and have attracted extensive attention worldwide. 
These complex systems combine many active compounds that may strike multiple 
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biological targets involved in neurodegenerative diseases [Glass et al.,, 2010; 
Lehàr et al., 2009]. 
 
1.8 Herbal remedies in neurodegenerative diseases  
Recently, a great number of natural medicinal plants have been tested for their 
therapeutic properties, showing that the raw extracts or the whole plants could be 
used as complementary agents in many neurodegenerative diseases. These 
properties are due mainly to the presence in the phytocomplexe of polyphenols, 
alkaloids and terpenes, among others, that are micronutrients produced by plants 
as secondary metabolites[Li et al., 2014]. Several evidences (epidemiological 
studies, animal studies, and human clinical trials) suggest the use of polyphenols 
in a wide range of pathologies associated with inflammation [Habauzit and 
Morand, 2012; Wright, 2013]. Polyphenols may act to protect the brain in a 
number of ways, including by protection of vulnerable neurons, the enhancement 
of existing neuronal function or by stimulating neuronal regeneration [Youdim 
and Joseph, 2001]. For example, polyphenols have been shown to protect neurons 
against oxidative stress [Li et al., 2005] and Aβ-induced- neuronal injury [Luo et 
al., 2002] and polyphenol-rich Ginkgo biloba extracts have been shown to be 
neuroprotective by protecting hippocampal neurons from nitric oxide- and Aβ-
induced neurotoxicity [Tchantchou et al., 2007].Among various polyphenols, 
curcumin, a polyphenolic antioxidant derived from the root of Curcuma longa has 
undergone extensive preclinical development, showing remarkable efficacy in 
neuroinflammatory disorders, particularly in AD [Hu et al., 2015].  
 
1.9 Curcumin: metabolism, bioavailability and biochemical effects in the 
brain 
Curcumin or diferuloylmethane (bis-α,β-unsaturated β-diketone) is a hydrophobic 
polyphenolic compound (mol mass of 368.38) present in the Indian spice turmeric 
(curry powder). It is the principal curcuminoid of turmeric (Curcuma longa), a 
member of the ginger family (Zingiberaceae). It has been used for centuries in 
Chinese traditional medicine and Indian medicine (Ayurvedic medicine) as a 
nociceptive, anti-inflammatory, and anti-shock drug to relieve pain and 
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inflammation in muscles and for the treatment of many pathological conditions, 
such as rheumatism, digestive and inflammatory disorders, intermittent fevers, 
urinary discharges, leukoderma and amenorrhoea as part of traditional medicine 
[Anand et al., 2008]. Turmeric products have been declared as safe not only by 
the FDA in the USA, and the Natural Health Products Directorate of Canada, but 
also by the Joint Expert Committee of the Food and Agriculture 
Organization/World Health Organization (FAO/WHO) (National Cancer Institute, 
1996). Thus, curcumin is a safe and non-toxic compound, which exhibits a wide 
range of pharmacological activities, such as anti-inflammatory, antioxidant, 
anticarcinogenic, antimutagenic, anticoagulant, antifertility, antidiabetic, 
antibacterial, antifungal, antiprotozoal, antiviral, antifibrotic, antivenom, antiulcer, 
hypotensive and hypocholesteremic activities [Amand et al., 2008; Prasad et al., 
2014]. The chemical structure of curcumin consists of two methoxyl groups, two 
phenolic hydroxyl groups, and three double conjugated bonds. The two aryl rings 
containing ortho-methoxy phenolic OH– groups are symmetrically linked to a β-
diketone moiety. The presence of intramolecular hydrogen atoms transfer at the β-
diketone chain of curcumin results in the existence of keto- and enol-tautomeric 
conformations in equilibrium (Figure7). Keto-enoltautomers of curcumin also 
exist in several cis and trans forms. The relative concentrations of cis and trans 
forms vary according to temperature, polarity of solvent, pH and substitution of 
the aromatic rings [Cornago et al., 2008]. Thus, a predominant keto form occurs 
in acidic and neutral solutions and as a stable enol form, which occurs in alkaline 
media. The amount of keto-enol-enolate of the heptadienone moiety in 
equilibrium plays acrucial role in the physicochemical properties of curcumin. 
The particular chemical structure of curcumin is predictive of the multi biological 
effects in human and animals. The o-methoxyphenol group and methylenic 
hydrogen are responsible for the antioxidant activity of curcumin, and curcumin 
donates an electron/hydrogen atom to reactive oxygen species. 
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 7. Chemical structures of tautomers of curcumin along with curcumin 2 
and curcumin 3.  
 
 
Curcumin interacts with a number of biomolecules through non-covalent and 
covalent binding. As stated above, the hydrogen bonding and hydrophobicity of 
curcumin, arising from the aromatic and tautomeric structures along with the 
flexibility of the linker group are responsible for the non-covalent interactions. 
The α,β-unsaturated β-diketone moiety covalently binds with thiols-residues in 
protein, through Michael reaction [Priyadarsini, 2013]. The β-diketo group is 
capable of chelating transition metals, thereby reducing the metal induced toxicity 
and some of the metal complexes exhibit improved antioxidant activity as enzyme 
mimics [Priyadarsini, 2013]. The alcoholic extract of turmeric contains three 
curcuminoids: curcumin (also referred as curcumin I, 77%), desmethoxycurcumin 
(curcumin II, 17 %), and bisdesmethoxycurcumin (curcumin III, 3%) (see Fig.7). 
In addition, turmeric also contains volatile oils (natlantone, tumerone and 
zingiberone), proteins, sugar and resins. Curcumin is insoluble in water. It is 
readily soluble in organic solvents, such as dimethylsulfoxide, acetone, and 
ethanol.  
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Figure 8. Degradation of curcumin under physiological conditions 
 
 
More than 90% decomposition of curcumin occurs in a serum free 0.1 M 
phosphate buffer (pH 7.2) at 37 °C. The degraded products have been identified as 
trans-6-(4′-hydroxy-3′-methoxyphenyl)- 2,4-dioxo-5-hexenal (major products), 
vanillin, vanillic acid, ferulic acid (4-hydroxy-3- methoxycinnamic acid) and 
feruloylmethane using high performance liquid chromatography (HPLC) and gas 
chromatography mass spectrophotometry (GC-MS) analyses [Wang et al., 1997] 
(see Fig.8). Among degradation products of curcumin, ferulic acid possesses three 
distinctive structural motifs, which contribute to its free radical scavenging 
activity. The presence of electron donating groups on the benzene ring (3 methoxy 
and more importantly 4-hydroxyl) of ferulic acid gives the additional property of 
terminating free radical chain reactions. Furthermore, carboxylic acid group in 
ferulic acid with an adjacent unsaturated C–C double bond provides additional 
attack sites for free radicals and thus preventing them from attacking the 
membrane. In addition, the carboxylic acid group in ferulic acid also acts as an 
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anchor for binding with the lipid bilayer and providing some protection against 
lipid peroxidation [Srinivasan et al., 2007; Kanski et al., 2002]. The addition of 
ascorbic acid, N-acetylcysteine and glutathione slow the decomposition of 
curcumin in both cell culture medium and 0.1 M phosphate buffer under alkaline 
conditions [Wang et al., 1997].  
In the brain, curcumin acts by modulating multiple pathways. The analgesic 
effects of curcumin are mediated by the suppression of nitrite, TNF-α, and 
capsaicin-induced TRPV1 activity, and through the descending noradrenergic and 
serotonergic systems [Yeon et al., 2010; Zhao et al., 2012]. Anti-inflammatory 
and antioxidant activities of curcumin are mediated by the inhibition of cytosolic 
phospholipase A2 (cPLA2), COX-2, 5-lipoxygenase (5-LOX), glutathione S-
transferases, down-regulation of inflammatory transcription factors, and 
upregulation of heme oxygenase-1 [Aggarwal et al., 2007]. Curcumin also 
interacts and modulates activities of DNA (cytosine-5)-methyltransferase-1, 
thioredoxin reductase, and protein kinases (such as protein kinase C, mammalian 
target of rapamycin, MAPK and Akt). Many of above mentioned enzymes 
contribute not only to its ability to interfere with multiple signalling cascades, 
such as cell cycle regulators, apoptotic proteins, pro-inflammatory cytokines, but 
also to its modulatory effects on proliferative regulators and transcription factors 
such as (NF-κB, Nrf2, Stat3, TNF-α, forkhead box O3a, AP-1 and CRAC 
[Shishodia, 2013]. It also inhibits secretion of interleukins and cytokines as well 
as the expression of human epidermal growth factor receptor [Chen et al., 2006]. 
Curcumin also inhibits the development of cancer cells, tumor growth and blocks 
angiogenesis and inflammation [Shehzad and Lee, 2013]. 
 
1.9.1 Bioavailability of curcumin and its analogs 
Delivery of curcumin to the body can be performed through oral, nasal, 
intraperitoneal, and intravenous injections. Despite its safety, curcumin presents a 
very low bioavailability, which is the greatest challenge for its therapeutic use in 
human [Prasad et al., 2014]. There are three major reasons for the low 
bioavailability:(a) its poor absorption, (b) its rapid metabolism, and (c) its rapid 
systemic elimination. In addition, curcumin has a short biological half-life in 
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circulation and visceral organs [Prasad et al., 2014]. In rodents, curcumin 
undergoes rapid metabolism by conjugation and reduction, and its disposition 
after oral dosing. However, information about comprehensive pharmacokinetic 
data is not available. It is reported that 10 mg/kg of curcumin given intravenously 
to rats yielded a maximum serum level of 0.36 ± 0.05 μg/mL, whereas 500 mg/kg 
of curcumin administered orally only yielded a 0.06 ± 0.01 μg/mL maximum 
serum level [Yang et al., 2007]. Furthermore, oral administration of curcumin at a 
dose of 2 g/kg results in a maximum serum concentration of 1.35 ± 0.23 μg/mL at 
time 0.83 h, while in humans the dose of 2 g of curcumin results in either 
undetectable or very low (0.006 ± 0.005 μg/mL at 1 h) serum levels [Shoba et al., 
1998].  
Very little information is available on pharmacokinetic of curcumin in humans. 
First phase I and II clinical trials of curcumin have been performed in patients 
with advanced colorectal cancer for up to 4 months at several doses (500, 1000, 
2000, 4000, 8000and 12,000 mg/day) without any toxicity [Sharma et al., 2001; 
Cheng et al., 2001].The serum concentration of curcumin usually peaks at 1–2 h 
after oral intake of curcumin and gradually declines within 12 h. The average peak 
serum concentrations after taking 4000 mg, 6000 mg and 8000 mg of curcumin 
were 0.51 ± 0.11 μM,0.63 ± 0.06 μM and 1.77 ± 1.87 μM, respectively. In this 
study, serum levels of curcumin peak after one hour, and two hours post-
administration they declined rapidly. So far, an upper level of toxicity has not 
been established for curcumin. Studies have shown that a dosage as high as 12 
g/day is safe and tolerable to humans with a few reporting mild side-effects [Goel 
et al., 2008; Jiao et al., 2009]. Studies on curcumin metabolism in animals 
indicate that it is rapidly metabolized through glucuronidation (Fig. 9) and 
sulfation or it is reduced to hexahydrocurcuminin liver, and intestine [Metzler et 
al., 2013]. Glucuronidation and sulfation of curcumin is catalyzed by UDP-
Glucuronosyltransferases(UGTs) and sulfotransferases in liver and intestine 
[Metzler et al., 2013]. 
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Figure 9. Curcumin metabolites after biotransformation. 
 
 
1.9.2 Different approaches to delivery curcumin to the brain 
It is well known that the brain and spinal cord are protected by the blood–brain 
barrier (BBB), a protective mechanism that controls cerebral homeostasis and 
provides the CNS with unique protection against all foreign matter [Roney et al., 
2005]. The BBB retards the entry of 98% of small molecules and 100% of large 
molecules in the brain. It is located at the level of the capillaries between the 
blood and cerebral tissue, and is characterized by the presence of tight 
intracellular junctions and polarized expression of many transport systems [Abbott 
et al., 2010]. BBB reduces the penetration of curcumin. In this case, the use of 
certain delivery systems (liposome, nanoparticles etc. [Ghalandarlaki et al., 2014; 
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Mourtas et al., 2014]) may prove particularly effective. These approaches have 
not only resulted in longer circulation and increase in the cellular permeability, 
but also resistance against metabolic processing leading to efficient delivery to 
tissues and higher half-life in the circulation. Some of these approaches have also 
allowed curcumin to penetrate the BBB effectively [Shoba et al., 1998; 
Ghalandarlaki et al., 2014]. The delivery of curcumin to the brain can enhance the 
adult hippocampus neurogenesis in the dentate gyrus region of hippocampus [Kim 
et al., 2008].As stated above, curcumin has a poor absorption rate and undergoes 
rapid metabolism which severely curtails its bioavailability. Piperine, a major 
alkaloidal constituent of black pepper (Piper nigrum), is a powerful inhibitor of 
hepatic and intestinal glucuronidation. Several studies have indicated that piperine 
increases the bioavailability and bioefficacy of curcumin by inhibiting 
glucuronidation [Shoba et al., 1998; Suresh and Srinivasan, 2010]. 
 
1.9.3 Biochemical activities and targets of curcumin action 
Curcumin mediates its effects through the modulation of transcription factors (NF-
κB,AP-1, STAT, and Nrf2), inflammatory cytokines (TNF-α, IL-1β, and IL-
6),enzymes (COX-2, LOX, MMP9, MAPK, mTOR, Akt), growth factors 
(VEGF,EGF, and FGF), growth factor receptors (EGFR, HER-2, and AR), 
adhesion molecules(ELAM-1, ICAM-1, VCAM-1), and apoptosis-related proteins 
(Bcl-2, caspases, DR, Fas) (Fig. 10) [Goel et al., 2008; Zhou et al., 2011]. These 
targets are associated with regulation of signal transduction processes involved in 
antioxidant, anti-inflammatory, antidepressant, antidiabetic, anti-hyperalgesic, 
anticarcinogenic, antimicrobial, hepatoprotective, thrombosuppressive, and 
antinociceptive effects of curcumin [Anand et al., 2008; Prasad et al., 2014]. It 
should be noted that most above mentioned activities of curcumin have been 
assigned to methoxy, hydroxyl, α,β-unsaturated carbonyl moiety or to diketone 
groups present in the curcumin structure. A major metabolite of curcumin is called 
as tetrahydrocurcumin(THC), which lacks α,β-unsaturated carbonyl moiety and is 
white in colour. It differs from curcumin in its chemical and biochemical activities 
[Aggarwal et al., 2014].Some investigators have indicated that curcumin exhibits 
both pro-oxidant and antioxidant properties, while THC mediates superior 
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antioxidant activities than curcumin. Curcumin increases the expression of HO-1 
through the activation of the Nrf2. In contrast, THC has no effect on HO-1 
expression [Aggarwal et al., 2014]. Other investigators have reported that THC 
mediates higher antioxidant activity due to its ability to better activate GSH 
peroxidase, glutathione-S-transferase, NADPH: quinine reductase as well as 
superior free radical quenching activities than curcumin [Aggarwal et al., 2014]. 
 
 
Figure 10. Effect of curcumin on gene expression, adipokines, transcription factors and 
enzymes. Curcumin mediates its effects through the modulation of transcription factors (NF-
κB,AP-1, STAT, and Nrf2), inflammatory cytokines (TNF-α, IL-1β, and IL-6),enzymes (COX-
2, LOX, MMP9, MAPK, mTOR, Akt), growth factors (VEGF,EGF, and FGF), growth factor 
receptors (EGFR, HER-2, and AR), adhesion molecules(ELAM-1, ICAM-1, VCAM-1), 
adipokines (resistin and leptin) and apoptosis-related proteins (Bcl-2, caspases, DR, Fas) (from 
Farooqi, 2016). 
 
 
1.9.4 Neuroprotective activities of curcumin 
It is well known that the brain hippocampus plays an important role in memory 
formation and spatial navigation. Adult hippocampal neurogenesis is closely 
related to memory formation [Snyder et al., 2005]. Progenitor cells located in the 
subgranular zone of the hippocampal dentate gyrus divide, proliferate, 
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differentiate, and give rise to new neurons [Jin et al., 2001]. Overall decline in 
cellular proliferation has been reported to occur during brain aging and 
stress[Cameron and McKay, 1999]. In the dentate gyrus of aged mice 
neurogenesis is promoted by low levels of ROS, expression of BDNF, caloric 
restriction, exercise, and physiological activation. Wnt-catenin signalling pathway 
contributes to neurogenesis through the maintenance of synaptic plasticity, 
survival, proliferation, and differentiation in embryonic and adult brains [Van 
Praaget al., 2002]. Curcumin mediates its neuroprotective effects and memory 
restoring effects through the prevention of oxidative stress [Cole et al., 2007]. In 
the okadaic acid-mediated neural impairment model, oral administration of 
curcumin significantly improves the memory function as assessed by both Morris 
water maze and passive avoidance tests [Rajasekar et al., 2013]. Curcumin not 
only reverses Aβ-mediated cognitive deficits and neuropathological alterations 
[Lim et al., 2001], but also promotes hippocampal neurogenesis through 
activation of the canonical Wnt pathway [Tiwari et al., 2014].  
 
1.9.5 Anti-inflammatory properties of curcumin 
Oxidative stress and neuroinflammation are interlinked with neurodegenerative 
processes in neurological disorders although it is difficult to establish the temporal 
sequence of their relationship. Pro-inflammatory transcription factor, NF-κB is 
redox sensitive. ROS stimulates NF-κB, which exists in the cytoplasm of neural 
cells as a heteromeric p50/p65 complexed with an inhibitory subunit, IκB. High 
oxidative stress promotes the dissociation NF-κB from NF-κB-IκB complex. This 
frees NF-κB and allows it to translocate to the nucleus, where it binds to genome 
through NF-κB response element, facilitating the expression of more than 200 
target genes including genes for inflammatory cytokines resulting in the onset of 
neuroinflammation. Many of genes contribute to cell proliferation, invasion, 
metastasis, and chemoresistance. Therefore, ROS trigger the release of 
inflammatory cytokines, which through the activation of phospholipasesA2, COX-
I2, and LOXs in turn enhance ROS production, thus establishing a vicious circle 
[Farooqui, 2014]. Curcumin retards neuroinflammation not only by inhibiting p65 
translocation to the nucleus and suppressing IκBα degradation in numerous cell 
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types, but also by blocking COXs and LOXs and the uptake of arachidonic acid 
by macrophages[Singh and Aggarwal, 1995]. By inhibiting NF-κB activation, 
curcumin suppresses the expression of various cell survival and proliferative 
genes, including Bcl-2, Bcl-xL, cyclin D1, interleukin (IL)-6,cyclooxygenase 2 
(COX-2) and matrix metallopeptidase (MMP)-9, and subsequently arrests cell 
cycle, inhibits proliferation, and induces apoptosis [Zhou et al., 2011]. In addition, 
Curcumin may also act by increasing the level and activity of proteins involved in 
antioxidative defense. Thus, curcumin enhances activities of protein kinases, and 
GST, CAT, SOD, UDP-glucuronosyltransferase (UGT), HO-1,andsirtuins. 
Activation of these enzymes not only contributes to neuroprotection, but is also 
essential for homeostasis in the vascular system [Zhang et al., 2015].  
Finally, numerous evidence demonstrates that curcumin can prevent 
neuroinflammation by modulating microglial activation [Lee et al., 2007]. 
Microglia mediated neuroinflammation is an important contributor to the 
inflammatory injury in various brain pathologies such as intracerebral hemorrhage 
(ICH).Curcumin could suppress ICH induced inflammatory injury and represent a 
novel herbal sources for ICH therapeutical strategy [Yang et al., 2014].Morover, 
the HIV-1 gp120 model of neuroinflammation increases ROS, TNF-α and MCP-1 
production in microglia, and induces cortical neuron apoptosis by affecting the 
delayed rectification and transient outward K+ channel current. Curcumin reduces 
production of ROS and inflammatory mediators in HIV-1-gp120-stimulated 
microglia, and protects cortical neurons against HIV-1-mediated apoptosis, most 
likely through inhibition of HIV-1 gp120-induced elevation of the delayed 
rectification and transient outward K+ current [Guo et al., 2013]. 
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2. Aim of the thesis 
The aim of this research project was the characterization of an in vivo model of 
neuroinflammation suitable for studying potential anti-inflammatory compounds, 
useful in the prevention and/or treatment of neurodegenerative (e.g., Parkinson's 
and Alzheimer's diseases, multiple sclerosis and amyotrophic lateral sclerosis) and 
psychiatric (psychosis, schizophrenia, depression) disorders, where inflammation 
is a main actor.   
Our attention was focused on curcumin, the main bioactive component in the 
rhizome of the turmeric plant (Curcuma longa). Curcumin is a safe and a highly 
pleiotropic molecule endowed with a wide range of beneficial activities, including 
anti-inflammatory, antitumor, anti-oxidative and cardiovascular protective effects, 
interacting with diverse molecular targets. 
 
The research activity of this project was focused on:  
 Characterization of the in vivo model of neuroinflammation, based on a 
single intraperitoneal injection of LPS. This model was characterized by 
molecular, biochemical and behavioral studies, that allowed us to identify 
a CNS inflammatory state.  
 Study of curcumin effects on the in vivo model of neuroinflammation. 
First, a dose-response study of curcumin was performed to choose the first 
efficacy dose able to prevent LPS-induced pro-inflammatory gene 
expression increase. Then, following an oral administration of curcumin 
(by gavage of a single dose for 2 consecutive days), molecular, 
biochemical and behavioral studies were performed to test the possible 
anti-inflammatory and neuroprotective role of curcumin.   
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3. Materials and Methods 
 
3.1 Animals and treatments  
Animal-related procedures were performed in accordance with National Institutes 
of Health guidelines for the care and use of laboratory animals and those of the 
Italian Ministry of Health (D.L. 26/2014). The study was approved by the OPBA 
of the University of Padova and the Italian Ministry of Health (Protocol number 
722/2015-PR).  
Three-month-old male C57BL/6J mice were housed under standard laboratory 
conditions with food and water ad libitum on a 12/12 h dark/light cycle (light on 
between 07:00 and 19:00 h). Before each experiment mice were handled during 3 
min daily for 6 days. The use of proper restraint and handling techniques reduces 
novelty-induced stress to animals and ensure greater results reliability. Animals 
were randomly divided into different experimental groups and intraperitoneally 
(i.p.) injected with either a single dose of LPS (0.5 or 5 mg/kg; E. Coli, 026:B6; 
Sigma, Italy) or vehicle (sterile endotoxin-free PBS; Life Technologies, Italy).  
For curcumin treatment, mice were orally treated with a single daily dose of either 
curcumin (5, 10 or 50 mg/Kg via gavage, in a 1% methylcellulose solution; 
Sigma-Aldrich, Italy) or vehicle following periodic fasting for two consecutive 
days. On the second day, one hour after curcumin treatment, mice were i.p. 
injected with a single dose of 5 mg/Kg LPS and sacrificed 2 h, 24h and 7 days 
post-injection for the analysis of animal behavior, cytokine profile, microglial 
morphology and neuronal cell loss (Fig. 11).   
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Figure 11: Schematic paradigm of mouse treatment. Mice were orally treated with either a 
single daily dose of curcumin or vehicle following periodic fasting for two consecutive days. On 
the second day, one hour after curcumin treatment, mice were i.p. injected with a single dose of 5 
mg/Kg LPS and sacrificed 2 h, 24h and 7 days post-injection.  
 
 
 
3.2 Measurements of body weight and food intake  
Body weight and food intake were measured every morning (9-10 am) for 7 days 
to minimize any variation due to the circadian rhythm. Food intake was obtained 
by subtracting remaining food, including any spilled food in cages, from a 
weighed aliquot of food  
 
3.3 Locomotor Activity: Open field test 
Open field test (OFT) is used for measuring anxiety and exploration as well as 
general locomotor activity levels [Tosini G, 2007]. The apparatus consists of four 
gray arenas (open field) delimited by a 30-cm-high wall (Fig. 12) exposed to an 
adjusted amount of light, which is measured with a Luxmeter. Arena was cleaned 
with 70% ethanol one hour before and at the end of each behavioral evaluation. 
Each mouse was allowed to freely move in the empty open field and locomotor 
activity was video-recorded during the one-hour session, using an overhead 
camera with a videotracking system.  Total distance traveled in the arena was 
analyzed using ANY-maze™ Video tracking (Stoelting Co.) 
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Figure 12: Gray arenas disposition during LMA test 
 
 
3.4 Novel Object Recognition (NOR) test  
The NOR test is used to evaluate recognition memory in murine models of CNS 
disorders. This test is based on the spontaneous tendency of rodents to spend more 
time exploring a new object with respect to a familiar one. The choice of 
exploring the new object reflects the capacity for learning and recognition.  
 
 
Figure 13: Novel object recognition test apparatus and schematic rappresentation. 
 
 
The apparatus consists of the same arena where LMA test was previously 
performed. Arena and object were cleaned with 70% ethanol one hour before and 
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at the end of each behavioral evaluation. The test was composed of two different 
sessions each lasting 10 min: 
 
- habituation phase: during this phase, two identical objects in shape and color 
were placed at the front of the arena and at equal distance from both sides, in 
order to allow the mouse to freely explore the objects Mice, previously habituated 
to the apparatus, were placed inside the arena for a 10-min period. Behavior was 
videotaped and the duration engaged in object investigation was determined from 
the video records by an observed who was blind to experimental treatments. 
Exploration was recorded when the animal’s nose or mouth was in direct contact 
with the object. Climbing or sitting on the object was not considered exploration 
[Frühauf et al., 2015].  
- retention phase: this test session was carried out 2 hours after habituation phase. 
Mice were placed back in the arena and one of the familiar object (object 2, Fig.13    
) was replaced by a novel object, different in shape and color. The times spent 
exploring the familiar and the novel object were videotaped for 10 min. 
The preference index was the calculated, considering the difference of time spent 
exploring the new and familiar objects, using the formula: 
(Tnovel) / (Tnovel+Tfamiliar) 
This index was used as a memory parameter. 
 
3.5 Brain area extraction 
Mice were rapidly sacrificed by cervical dislocation 2 hours, 24 hours and 7 days 
after treatments, limiting possible manipulation induced-stress. Brains were gently 
removed from the skull and immediately placed on a glass plate on ice. Frontal 
cortex, hippocampus, striatum, cerebellum and hypothalamus were dissected, 
placed into sterile tubes (Eppendorf®) and stored at -80°C for subsequent 
analysis.  
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3.6 RNA extraction  
Total RNA was extracted from frontal cortex, hippocampus, striatum, cerebellum 
and hypothalamus tissues by TRIzol® Reagent (Life Technologies), according to 
the manufacturer's instructions. One mL TRIzol® Reagent was added per 30-50 
mg of brain tissue. Tissues were homogenized using a power homogenizer, 
immediately placed on ice for 15 min and then incubated for 5 min at room 
temperature (RT) to permit complete dissociation of the nucleoprotein complex. 
0.2 mL of chloroform per 1 mL of TRIzol® Reagent were subsequently added for 
homogenization. Tubes were capped and shook vigorously by hand for 15 s and 
incubated for 15 min at 4°C. Samples were centrifuged at 12,000 × g for 15 min at 
4°C, to allow the mixture to separate into a lower red phenol/chloroform phase, an 
interphase, and a colourless upper aqueous phase. RNA remained exclusively in 
the aqueous phase. The upper aqueous phase was ~50% of the total volume. 
Aqueous phase was removed by angling the tube at 45° and pipetting the solution 
out into a new labelled tube, paying attention to avoid drawing any of the 
interphase or organic layer into the pipette when removing the aqueous phase. 0.5 
mL of 100% isopropanol/mL of TRIzol® Reagent used for homogenization were 
added to the aqueous phase and incubated at RT for 10 min before centrifuging at 
12,000 × g for 10 min at 4°C. RNA is often invisible prior to centrifugation and 
forms a gel-like pellet on the side and bottom of the tube. After centrifugation 
supernatant was removed from the tube, leaving only the RNA pellet. One mL of 
75% ethanol/mL of TRIzol® Reagent used in the initial homogenization was used 
to wash the pellet. Samples were centrifuged at 7,500 × g for 5 min at 4°C, 
supernatant was discarded and RNA pellet was vacuumed or air dried for 5–10 
min, avoiding the RNA to dry completely. Finally, pellet was dissolved in 
diethylpyrocarbonate (DEPC) water and stored at -80°C. RNA integrity and 
quantity were determined by spectrophotometric analysis (NanoDrop 2000, 
Thermo Fisher Scientific Inc.). One microgram of RNA was reverse transcribed 
with Superscript IV Reverse Transcriptase using random oligonucleotides (Life 
Technologies).  
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3.7 Real-time RT-PCR analysis  
The real-time RT-PCR reaction was performed in a MX 3000P thermal cycler in a 
final volume of 10 µl, containing 100 nM of each primer pair (Table 2) and 1X 
SYBR green JumpStart Taq ReadyMix (Sigma). The PCR cycling conditions 
comprised an initial denaturation step at 94°C for 4 min, followed by 45 cycles of 
denaturation at 94°C for 20 s, annealing at 60°C for 15 s and extension phase at 
72°C for 30 s, followed by a dissociation thermal profile at 95°C for 1 min, 55°C 
for 30 s, and 95°C for 30 s. Amounts of each gene product were calculated using 
linear regression analysis from standard curves, demonstrating amplification 
efficiencies ranging from 90 to 100%. Dissociation curves were generated for 
each primer pair, showing single product amplification. Relative mRNA levels 
were obtained after normalization to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) levels.  
 
                       Table 2: Gene names and primer used for Real-time PCR analysis 
TNF-α 
F CAAGTGGAGGAGCAGCTGGA 
R CATCGGCTGGCACCACTAGT 
IL-1β 
F CTGGTGTGTGACGTTCCCATTA 
R CCGACAGCACGAGGCTTT 
IL-6 
F GAGGATACCACTCCCAACAGACC 
R AAGTGCATCATCGTTGTTCATACA 
IL-18 
F AGGTGGGGAGGGTTTGTGTT 
R TGCAGCCTCGGGTATTCTGT 
COX-2 
F GCTGGCCTGGTACTCAGTAGGTT 
R CGAGGCCACTGATACCTATTGC 
iNOS 
F TGTACCCTCAGTTCTGCGCC 
R TGTTGGGGCAAGCTGAGAGG 
POMC 
F GCCCAAGGACAAGCGTTACG 
R TGCGCGTTCTTGATGATGGC 
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3.8 Protein extraction 
Proteins were extracted from brain regions of interest (frontal cortex, striatum, 
hippocampus, cerebellum). 50 mL of lysis solution [890 µL NP-40 cell lysis 
buffer (Invitrogen), 100 µL protease inhibitor cocktail (Sigma Aldrich) and 10 µL 
of 0.1 M Pefabloc SC (Sigma Aldrich)] was added per mg of brain tissue. Tissues 
were homogenized using a power homogenizer and immediately placed on ice for 
45 min. Samples were then cleared by centrifugation at 14,000 × g for 20 min at 
4°C. The supernatants were transferred into new labelled tubes and stored at -
20°C until analysis (by avoiding repeated cycles of freezing/thawing).  
 
3.9 Bicinchoninic acid (BCA) protein assay     
Protein amount was determined by the BCA method, using the BCA Protein Assay 
Reagent Kit (Pierce) and bovine serum albumin (BSA, Pierce) as standard, 
following to the manufacturer’s protocol. In brief, 100 µL of working reagent, 
containing sodium carbonate, sodium bicarbonate, bicinchoninic acid, cupric 
sulphate, sodium tartrate were mixed with tissue lysate. The mixture was 
incubated for 30 min at 37°C. All samples were then measured for their 
absorbance at 570 nm, using a Microplate Reader (1420 Victor2 Multilabel 
Counter, Perkin Elmer Wallac). Total amount of protein was calculated from the 
BSA calibration curve and expressed in µg/ml of tissue.  
 
3.10 Enzyme-linked immunosorbent assay (ELISA)  
The TNF-α levels were analyzed by ELISA, using a commercially available 
ELISA kit (Antigenix America, Huntington Station, NY, USA), according to the 
manufacturer's instructions. Cytokine concentration was determined with 
reference to a standard curve obtained with known amounts of TNF-α. A 96-well 
plate was incubated ON at 4°C with a Coating Antibody Working Solution (1 
µg/mL). After solution removal and four washings with Washing Solution (0.05% 
Tween-20 in 1X PBS), 100 µL of Coating Stabilizer/Blocking Reagent were 
placed in each well for 1 hour. Solution was then removed and standard and 
samples were transferred in the plate for 2 hours. At the end of incubation, plate 
was extensive washed (4 times) with washing solution and incubated with 
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Detection Antibody Working Solution for 1 hour at RT. After extensive rinsing (4 
times) with Washing Solution, plate was incubated with an Avidin-HRP Working 
Solution for 30 min at RT, washed with Washing Solution and incubated with a 
Colour Development Solution for 10 min at RT. Finally, Stop Solution (2M 
sulfuric acid) was added and the plate was read at 450 nm, using a Microplate 
Reader (Victor2 Multilabel Counter). TNF-α concentrations (pg/mg protein) were 
determined by reference to standard curves obtained with known amounts of 
TNF-α.  
 
3.11 Immunohistochemistry  
Brains were gently extracted from the skull, washed in PBS (3 times), fixed in 4% 
paraformaldehyde for 2 hours at 4°C, cryopreserved in a sucrose gradient (12%, 
16%, 18%, 30%) for 4 consecutive days and then embedded in Tissue-Tek OCT 
compound (Sakura Finetek), as previously described [Majno and Joris, 2004]. 
Frozen tissues were cryostat sectioned (12 µm), mounted onto SuperFrost glass 
slides (Fisher), and stored at -20°C until use.  
Immunofluorescence experiments were performed by removing OCT excess, 
surrounding slides with a PAP-PENto avoid fluid loss, and rehydrating slides with 
PBS for 10 min at RT. Immunofluorescence staining involving mouse primary 
antibodies was performed using a “Mouse on Mouse” Kit (Vector Laboratories). 
All other immunofluorescence experiments were performed by first blocking non-
specific staining with a blocking solution containing 5% normal goat serum 
(NGS) and 0.1% Triton X-100 in PBS for 1 h. Sections were then washed 3 times 
with PBS for 10 min at RT and sequentially incubated with primary (2 hours) and 
secondary (1 hours) antibodies diluted in blocking solution. The following 
primary antibodies were used: rabbit polyclonal anti-ionized calcium binding 
adaptor molecule 1 (Iba1) (1:800, Wako Chemicals USA Inc., Richmond, VA, 
USA) and mouse monoclonal anti-tyrosine hydroxylase (TH, (1:800, Sigma 
Aldrich). The fluorescent-conjugated secondary antibodies used included the 
Alexa Fluor 488 and 555 series (1:1000; Invitrogen). Sections were counterstained 
(2 min at RT) with 4′,6-diamidine-2′-phenylindole dihydrochloride (DAPI; Sigma) 
to visualize nuclei, and mounted with Fluoromount-G mounting medium (Fisher 
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Scientific, Milan, Italy). All images were captured with a confocal laser-scanning 
microscope (Zeiss LSM 800; Carl Zeiss AG, Oberkochen, Germany). 
3.12 Plasma and tissue sample preparation for HPLC-MS analysis 
Fifty µL of analytical standard (137 µg/mL benzanilide) and 200 µL of methanol 
were added to 100 µL of plasma samples.  Samples were stirred, centrifugated for 
10 min at 13, 000 rpm, then supernatants were collected and placed in vials. 
Brain were homogenized using a power homogenizer and added of 50 µL of 
analytical standard (137 µg/mL benzanilide) and 500 μL/brain of methanol. After 
stirring, samples were sonicated in an ultrasonic bath for 10 min, centrifuged at 
13, 000 rpm for 10 min, then supernatants were collected and placed in vials. 
 
3.13 HPLC-MS analysis 
An Agilent series 1260 HPLC chromatograph equipped with a Prostar 410 auto-
sampler (Varian, Cernusco Sul Naviglio, Milan, Italy) coupled with a Varian 320 
TQD MS spectrometer was used as HPLC-MS system. The mass spectrometer 
was equipped with electrospray ionization (ESI) source as the interface and 
analysis was conducted in positive ion mode. Analyses were performed on 
Phenomenex Kinetex EVO C-18 100A, 100 x 3 mm 5 µm column. The mobile 
phase was composed of solvent A (water-formic acid, 100:1.0 v/v) and solvent B 
(acetonitrile). A gradient program was used as follows: 0 → 9th min: A:B (80:20) 
→ A:B (5:95) 9 → 15th min: A:B (5:95) → A:B (5:95) 15 → 15.5th min: A:B 
(5:95) → A:B (80:20) 15.5→20th min: A:B (80:20) → A:B (80:20). The mobile 
phase flow rate was 200 μL/min and the injection volume was 10 μL. The ESI 
source was set in positive ionization mode. Quantification was performed using 
multiple reaction monitoring (MRM) with m/z 369 → 177 transition for curcumin 
and m/z 198 → 105 transition for benzanilide standard.  
 
Analyte Mass (M+H) Fragment 
Curcumin 369 177 
Benzanilide 198 105 
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3.14 Statistical Analysis  
Statistical comparisons were made using Student’s t test or one-way analysis of 
variance (ANOVA) followed by post-hoc tests for either selected or multiple 
comparisons. Values are expressed as mean ± standard error of the mean (SEM). 
All statistical tests were performed with GraphPad Prism software version 3.03. 
Significance level was set at p < 0.05. Additional details are provided in the figure 
legends, where appropriate. 
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4. Results 
 
4.1 Effect of systemic LPS administration on body weight and food intake. 
Mice were i.p. injected with either vehicle (sterile PBS) or two doses of LPS (0.5 
and 5 mg/Kg) and body weight and food intake were monitored daily for 7 days 
after injection. Both doses of LPS induced a significant decrease in body weight 
24 hours after LPS injection (- 3.20 ± 0.34 g and - 2.90 ± 0.27 g, with 0.5 and 5 
mg/Kg LPS, respectively), compared with control group (0.02 ± 0.009 g) . On day 
2 after treatment, body weight was significantly reduced only in 5 mg/Kg LPS-
treated mice (-0.58 ± 0.22). From the third day, mice completely recovered LPS-
induced body weight loss (Fig. 14). 
 
 
 
Figure 14: Effect of LPS on body weight changes in mice. Mice were treated with a 
single intraperitoneal injection of vehicle (sterile PBS; green line) or two doses of LPS [0.5 
mg/Kg (ochre line) or 5 mg/Kg (red line)] and body weight change was monitored daily for 
7 days after injection. Data are means ± SEM (n=10 animals/group). *p<0.05 and 
***p<0.001 vs vehicle. Student’s t-test. 
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Food intake was also monitored daily for 7 days after LPS treatment. Both LPS 
doses induced a significant decrease of total food intake up to 4 days after 
injection. Starting from day 5 total food intake gradually returned to control 
values (Fig. 15). 
 
 
 
Figure 15: Effect of LPS on food intake in mice. Mice were treated with a single 
intraperitoneal injection of vehicle (sterile PBS; green line) or two doses of LPS [0.5 
mg/Kg (ochre line) or 5 mg/Kg (red line)] and total food intake was monitored daily for 
7 days after injection. Data are means ± SEM (n=10 animals/group). **p<0.05 and 
***p<0.001 vs vehicle. Student’s t-test.  
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4.2 Effect of systemic LPS administration on gene expression profile of major 
pro-inflammatory molecules in different brain areas. 
In order to evaluate the effect of a systemic injection of 0.5 and 5 mg/Kg LPS on 
brain inflammation, mRNA levels of different inflammation-related cytokines and 
enzymes, known to be involved in neuroinflammation, were measured. In 
particular, gene expression of TNF-α, IL-1β, IL-6, IL-18, COX-2 and iNOS were 
analyzed in frontal cortex, striatum, hippocampus and cerebellum, by real-time 
RT-PCR (see “Materials and Methods” section for more details). With regard to 
TNF-α , its mRNA levels were significantly increased in 5 mg/Kg LPS (red lines) 
versus control (green lines) animals within the first 24 hours after LPS treatment 
in all brain areas analyzed, with the exception of cerebellum, where a significant 
increase was observed only 2 hours post-treatment. No significant differences in 
TNF-α mRNA levels were found between 0.5 mg/Kg LPS (ochre lines) and 
control (green lines) mice (Fig. 16).  
 
 
Figure 16: Effect of LPS on TNF-α mRNA levels in different brain areas. Mice were 
treated with a single i.p. injection of vehicle (sterile PBS; green lines) or two doses of LPS [0.5 
mg/Kg (ochre lines) or 5 mg/Kg (red lines)] and mRNA levels of TNF-α were evaluated in 
frontal cortex, striatum, hippocampus and cerebellum, 2 hours, 24 hours and 7 days post-
treatment by real-time RT-PCR. Data are means ± SEM (n=6 animals/group). **p<0.01 vs 
vehicle. ANOVA followed by post-hoc Dunnett’s test. 
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IL-1β, IL-6 and iNOS mRNA levels (Figs. 17,18,19) increased in all brain areas 2 
hours after 5 mg/Kg LPS treatment (red lines), declining to control levels by 24 
hours post-treatment. No significant gene expression changes with low dose of 
LPS (0.5 mg/Kg, ochre lines) were observed. 
 
 
 
Figure 17: Effect of LPS on IL-1β mRNA levels in different brain areas. Mice were treated 
with a single i.p. injection of vehicle (sterile PBS; green lines) or two doses of LPS [0.5 mg/Kg 
(ochre lines) or 5 mg/Kg (red lines)] and mRNA levels of IL-1β were evaluated in frontal cortex, 
striatum, hippocampus and cerebellum, 2 hours, 24 hours and 7 days post-treatment by real-time 
RT-PCR. Data are means ± SEM (n=6 animals/group). **p<0.01 vs vehicle. ANOVA followed 
by post-hoc Dunnett’s test. 
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Figure 18: Effect of LPS on IL-6 mRNA levels in different brain areas. Mice were treated 
with a single i.p. injection of vehicle (sterile PBS; green lines) or two doses of LPS [0.5 
mg/Kg (ochre lines) or 5 mg/Kg (red lines)] and mRNA levels of IL-6 were evaluated in 
frontal cortex, striatum, hippocampus and cerebellum, 2 hours, 24 hours and 7 days post-
treatment by real-time RT-PCR. Data are means ± SEM (n=6 animals/group). **p<0.01 vs 
vehicle. ANOVA followed by post-hoc Dunnett’s test. 
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Figure 19: Effect of LPS on iNOS mRNA levels in different brain areas. Mice were 
treated with a single i.p. injection of vehicle (sterile PBS; green lines) or two doses of LPS 
[0.5 mg/Kg (ochre lines) or 5 mg/Kg (red lines)] and mRNA levels of iNOS were evaluated 
in frontal cortex, striatum, hippocampus and cerebellum, 2 hours, 24 hours and 7 days post-
treatment by real-time RT-PCR. Data are means ± SEM (n=6 animals/group). **p<0.01 vs 
vehicle. ANOVA followed by post-hoc Dunnett’s test. 
 
Interestingly, unlike the previously analyzed pro-inflammatory molecules, 
treatment with both LPS doses did not induce any significant change in IL-18 
gene expression levels in the brain regions analyzed (Fig. 20).  
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Figure 20: Effect of LPS on IL-18 mRNA levels in different brain areas. Mice were treated 
with a single i.p. injection of vehicle (sterile PBS; green lines) or two doses of LPS [0.5 mg/Kg 
(ochre lines) or 5 mg/Kg (red lines)] and mRNA levels of IL-18 were evaluated in frontal 
cortex, striatum, hippocampus and cerebellum, 2 hours, 24 hours and 7 days post-treatment by 
real-time RT-PCR. Data are means ± SEM (n=6 animals/group). ANOVA followed by post-
hoc Dunnett’s test. 
 
 
 
Finally, mRNA levels of COX-2 were evaluated. Both doses of LPS significantly 
increased COX-2 mRNA levels in frontal cortex, striatum, hippocampus and 
cerebellum 2 hours after LPS injection. Furthermore, highest LPS dose (5 mg/kg) 
maintained these levels elevated in striatum and cerebellum up to 24 hours. To 
note that basal mRNA levels of COX-2 (green lines) were higher in frontal cortex 
and hippocampus compared to striatum and cerebellum, where LPS effect was 
evident also 24 hours post-treatment.  
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Figure 21: Effect of LPS on COX-2 mRNA levels in different brain areas. Mice were 
treated with a single i.p. injection of vehicle (sterile PBS; green lines) or two doses of LPS 
[0.5 mg/Kg (ochre lines) or 5 mg/Kg (red lines)] and mRNA levels of COX-2 were evaluated 
in frontal cortex, striatum, hippocampus and cerebellum, 2 hours, 24 hours and 7 days post-
treatment by real-time RT-PCR. Data are means ± SEM (n=6 animals/group). **p<0.01 vs 
vehicle. ANOVA followed by post-hoc Dunnett’s test. 
 
4.3 Concentration of curcumin in brain and plasma after oral administration.  
To verify whether curcumin could reach the CNS, mice were orally treated with 
50 mg/Kg curcumin for 2 consecutive days and then i.p. injected with 5 mg/Kg 
LPS. Two hours after LPS injection, mice were sacrificed and plasma and brains 
were analyzed by HPLC.  Brain levels of curcumin were 1.80 ± 0.50 µg/g and this 
amount did not differ after LPS stimulation (2.71 ± 1.40 µg/g) (Table 3). 
Moreover, no metabolites in the brain tissue samples were detected, although 
some glucuronide metabolites were found in plasma (data not shown).  
 
 
 
 
A 
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Table 3. Concentration of curcumin in brain and plasma after oral administration.  
 
Curcumin (50mg/Kg) was administered one hour before LPS (5 mg/Kg) injection. 
Concentration of curcumin in the brain and plasma was evaluated 2h after LPS treatment. 
Data are means ± SEM (n=5 animals/group).  
 
4.4 Effect of curcumin on gene expression profile in LPS-induced 
inflammatory state. 
To test possible anti-inflammatory properties of curcumin in the CNS, mice were 
orally pre-treated with increasing doses (5, 10 and 50 mg/kg) of curcumin before 
LPS treatment. As shown in Fig. 11, curcumin was administered via gavage, with 
a single daily dose, for 2 consecutive days, before LPS injection to induce an 
inflammatory response in the CNS. Two hours post-treatment with 5 mg/kg LPS 
mice were sacrificed and brain areas collected for real-time RT-PCR analysis, as 
previously described (see “Materials and Methods” section). Low basal levels of 
TNF-α, IL-1β, IL-6, iNOS and COX-2 gene expression remained unchanged after 
treatment with increasing doses of curcumin (Figs. 22,23,24,25,26). Conversely, 
pre-treatment with curcumin, dose-dependently, suppressed LPS-induced increase 
of mRNA levels of TNF-α, IL-1β and COX-2 in all brain areas (Figs.22,23,26), 
while limiting expression of IL-6 and iNOS to striatum and cerebellum 
(Figs.24,25).  
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Figure 22: Effect of curcumin on TNF-α mRNA levels in LPS-treated mice. Mice were 
treated for 2 consecutive days with a single daily dose of vehicle, 5, 10 or 50 mg/kg curcumin 
before LPS treatment. mRNA levels of TNF-α were evaluated in frontal cortex, striatum, 
hippocampus and cerebellum, 2 hours after treatment with LPS, by real-time RT-PCR. Data are 
means ± SEM (n=6 animals/group). *p<0.05, ***p<0.001 vs vehicle; #p<0.05, ##p<0.01 and 
###p<0.001 vs LPS-treatment. ANOVA followed by post-hoc Tukey’s test. 
 
 
A 
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Figure 23: Effect of curcumin on IL-1β mRNA levels in LPS-treated mice. Mice were treated 
for 2 consecutive days with a single daily dose of vehicle, 5, 10 or 50 mg/kg curcumin before 
LPS treatment. mRNA levels of IL-1β were evaluated in frontal cortex, striatum, hippocampus 
and cerebellum, 2 hours after treatment with LPS, by real-time RT-PCR. Data are means ± SEM 
(n=6 animals/group). ***p<0.001 vs vehicle; ##p<0.01 and ###p<0.001 vs LPS-treatment. 
ANOVA followed by post-hoc Tukey’s test. 
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Figure 24: Effect of curcumin on IL-6 mRNA levels in LPS-treated mice. Mice were treated 
for 2 consecutive days with a single daily dose of vehicle, 5, 10 or 50 mg/kg curcumin before LPS 
treatment. mRNA levels of IL-6 were evaluated in frontal cortex, striatum, hippocampus and 
cerebellum, 2 hours after treatment with LPS, by real-time RT-PCR. Data are means ± SEM (n=6 
animals/group). *p<0.05, **p<0.01 and ***p<0.001 vs vehicle; ###p<0.001 vs LPS-treatment. 
ANOVA followed by post-hoc Tukey’s test. 
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Figure 25: Effect of curcumin on COX-2 mRNA levels in LPS-treated mice. Mice were 
treated for 2 consecutive days with a single daily dose of vehicle, 5, 10 or 50 mg/kg curcumin 
before LPS treatment. mRNA levels of COX-2 were evaluated in frontal cortex, striatum, 
hippocampus and cerebellum, 2 hours after treatment with LPS, by real-time RT-PCR. Data are 
means ± SEM (n=6 animals/group). ***p<0.001 vs vehicle; #p<0.05, ##p<0.01 and ###p<0.001 
vs LPS-treatment. ANOVA followed by post-hoc Tukey’s test. 
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Figure 26: Effect of curcumin on iNOS mRNA levels in LPS-treated mice. Mice were treated 
for 2 consecutive days with a single daily dose of vehicle, 5, 10 or 50 mg/kg curcumin before LPS 
treatment. mRNA levels of iNOS were evaluated in frontal cortex, striatum, hippocampus and 
cerebellum, 2 hours after treatment with LPS, by real-time RT-PCR. Data are means ± SEM (n=6 
animals/group). *p<0.05, **p<0.01 and ***p<0.001 vs vehicle; #p<0.05 and ##p<0.01 vs LPS-
treatment. ANOVA followed by post-hoc Tukey’s test.  
 
 
 
 
 
 
 
 
 
 
A 
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4.5 Effect of curcumin on LPS-induced body weight and food intake changes. 
Mice were orally pre-treated with 50 mg/Kg curcumin before LPS treatment and 
body weight and food intake were monitored daily for 7 days after LPS injection. 
Curcumin completely prevented LPS-induced body weight loss during the first 2 
days after treatment. Interestingly, treatment with curcumin alone induced a 
significant increase in mouse body weight during the 24 hours after treatment (+ 
1.63 g ± 0.15 g)  (Fig. 27). 
Food intake was also monitored daily for 7 days after LPS treatment. Pre-
treatment with curcumin completely prevented LPS-induced food intake reduction 
during the 4 days after treatment (orange line). Starting from day 5 curcumin 
treatment induced a significant increase in food intake in mice treated with LPS 
(orange line) compared to control (green line) and LPS-treated group (red line) 
(Fig. 28). 
 
 
Figure 27: Effect of curcumin on LPS-induced body weight 
changes. Mice were orally pre-treated with 50 mg/Kg curcumin before 
treatment with vehicle or 5 mg/Kg LPS and body weight change was 
monitored daily for 7 days after LPS injection. Data are means ± SEM 
(n=10 animals/group). *p<0.05, ***p<0.001 vs vehicle. 
##
p<0.01 and 
###
p<0.001 vs LPS. Student’s t-test. 
 73 
 
  
Figure 28: Effect of curcumin on LPS-induced food intake changes. Mice 
were orally pre-treated with 50 mg/Kg curcumin before treatment with 
vehicle or 5 mg/Kg LPS and food intake was monitored daily for 7 days after 
LPS injection. Data are means ± SEM (n=10 animals/group). *p<0.05, 
**p<0.01 vs vehicle. 
#
p<0.05 and 
##
p<0.01 vs LPS. Student’s t-test. 
 
4.6 Effect of LPS and curcumin on hypothalamic proopiomelanocortin 
(POMC) gene expression. 
Based on the observed effects of LPS and curcumin pre-treatment on body weight 
and food intake changes, a preliminary analysis on their effects on the 
hypothalamic expression of the feeding-related neuropeptide POMC [Millington, 
2007] was performed. As shown in Fig. 29, the mRNA expression of the 
anorexigenic gene POMC was significantly increased by LPS 2 hours after 
injection, while pre-treatment with curcumin decreased LPS-induced increase of 
gene expression. However, a direct effect of curcumin on POMC gene expression 
was not observed. Furthermore, no significant differences in POMC mRNA levels 
were found 24 hours and 7 days after LPS-treatment, both in the absence and 
presence of curcumin pre-treatment (data not shown). 
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Figure 29: Effect of LPS and curcumin on POMC 
mRNA levels in the hypothalamus. Mice were orally pre-
treated 50 mg/Kg curcumin before treatment with vehicle 
or a single dose of LPS And mRNA levels of POMC were 
evaluated in the hypothalamus 2 hours post-treatment, by 
real-time RT-PCR. Data are means ± SEM (n=6 
animals/group). *p<0.05 vs vehicle; #p<0.05 vs LPS 
treatment. ANOVA followed by post-hoc Tukey’s test. 
 
4.7 Effect of curcumin on TNF-α protein expression in LPS-induced 
inflammatory state.  
To further support the anti-inflammatory effect of curcumin on LPS-induced 
neuroinflammation, TNF-α protein levels were measured in different brain areas. 
Mice were treated with vehicle or 50 mg/kg LPS before LPS injection (5 mg/kg), 
brain areas were collected 2 hours, 24 hours and 7 days after systemic LPS 
administration and TNF-α content was determined by ELISA. Basal protein 
expression of TNF-α was not modified by curcumin treatment in all brain areas 
analyzed (orange bars in Fig. 30). Two hours post-treatment, LPS induced a 
significant increase in TNF-α protein expression in all areas analyzed with the 
exception of striatum. Moreover, TNF-α levels remained significantly higher up to 
7 days in frontal cortex. Pre-treatment with curcumin decreased to control values 
the LPS-induced increase of TNF-α protein expression (Fig. 30). 
# 
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Figure 30: Effect of curcumin on TNF-α protein levels in in LPS-treated mice. Mice were 
treated for 2 consecutive days with a single daily dose of vehicle or 50 mg/kg curcumin before 
LPS treatment. Protein expression of TNF-α was evaluated in frontal cortex, striatum, 
hippocampus and cerebellum 2 hour, 24 hours and 7 days after treatment with LPS, by ELISA. 
Data are means ± SEM (n=6 animals/group). *p<0.05, **p<0.01 vs vehicle; 
#
p<0.05 and 
###
p<0.001 vs LPS-treatment. ANOVA followed by post-hoc Tukey’s test. 
 
4.8 Effect of curcumin on LPS-induced microglia morphological changes. 
Since activation of microglia is accompanied by morphological changes 
[Nimmerjahn et al., 2005], immunohistochemical analysis was performed to 
evaluate the possible effect of curcumin on microglial morphology. Two hours 
after LPS treatment, Iba1 staining in frontal cortex showed an increased cellular 
density and cells characterized by a morphology typical of primed and reactive 
microglia: presence of enlarged and less round cell body and thicker and more 
ramified ramifications (middle panel in Fig. 31). Curcumin pre-treatment 
completely prevented LPS-induced morphological changes in microglia and Iba1 
staining showed cells characterized by a small cell body and many thin 
A 
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ramifications (lower panel in Fig. 31), similar to that of the control mice (upper 
panel in Fig. 31) 
 
 
Figure 31: Effect of curcumin on microglial cell morphology in cerebral cortex. Mice were 
treated for 2 consecutive days with a single daily dose of vehicle or 50 mg/kg curcumin before 
LPS treatment (5 mg/Kg) and sacrificed 2 hours after LPS injection. Brain sections were 
immunostained with Iba1 specific microglial marker and counterstained with DAPI to visualize 
cell nuclei. Experiments were performed 4 times and representative confocal images are shown.  
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4.9 Effect of curcumin on locomotor activity in LPS-treated mice. 
To evaluate the effects of LPS and curcumin on spontaneous behavior activity, 
mice pre-treated with curcumin were i.p. injected with vehicle or LPS and  
locomotor activity was assessed by LMA test as described in “Materials and 
Methods” 24 hours and 7 days after LPS injection. Twenty-four hours after LPS 
treatment, mice showed a marked decrease of  total distance travelled in the arena 
(38.55 ± 12.01 m), compared to control mice (124.26 ± 22.30 m) (Fig. 32A).  This 
effect  was evident until 7 days post-treatment (163.32 ± 12.94 m, control mice 
and 104.63 ± 16.34 m, LPS-treated mice) (Fig. 32B). Pre-treatment with curcumin 
(50 mg/Kg) abolished the inhibitory effect of LPS on locomotor activity (112.19 ± 
22.91 m after 24 hours and 127.99 ± 25.49 m 7 days after LPS injection) (Fig. 
32A and B). 
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Figure 32: Effect of curcumin on locomotor activity in LPS-treated mice. Mice were 
orally pre-treated with 50 mg/Kg curcumin before treatment with vehicle or 5 mg/Kg 
LPS and spontaneous activity was assessed by LMA test 24 hours (A) and 7 days (B) 
after LPS injection. Data are means ± SEM (n = 12 animals/group). *p <0.05, **p <0.01 
vs vehicle; 
#
p <0.05, 
###
p <0.001 vs LPS treatment. Student’s t test. 
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4.10 Effect of curcumin on dopaminergic neurons in the substantia nigra and 
ventral tegmental area (VTA) of LPS-treated mice. 
To investigate possible neuroprotective effect of curcumin on the dopaminergic 
neurons of substantia nigra and ventral tegmental area, mice were treated as 
described and damage of the dopaminergic neurons were observed by using 
tyrosine-hydroxylase (TH) staining 7 days after LPS treatment.  Fig. 33 showed 
that 7 days after injection, LPS induced a slight reduction in the number of TH-
labeled neurons (middle panel), while pre-treatment with curcumin protected from 
dopaminergic neuronal cell loss (lower panel). 
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Figure 33: Effect of curcumin on dopaminergic neurons in the substantia nigra and 
VTA of LPS-treated mice. Mice were treated for 2 consecutive days with a single daily 
dose of vehicle or 50 mg/kg curcumin before LPS treatment (5 mg/Kg) and sacrificed 7 
days after LPS injection. Brain sections were immunostained with anti-TH antibody and 
counterstained with DAPI to visualize cell nuclei. Experiments were performed 3 times and 
representative confocal images are shown.  
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4.11 Effect of systemic LPS administration on memory function.  
To evaluate the effect of LPS on recognition memory, mice systemically treated 
with LPS were subjected to NOR test as described in "Materials and Methods" 7 
days and 1 month after LPS injection. LPS decreased the preference index 
compared to the control group at both time points (Fig. 34), indicating a memory 
impairment in LPS-treated animals.   
 
Figure 34: Effect of systemic LPS administration on memory. Mice were treated with 5mg/Kg 
LPS and recognition memory was assessed 7 days and 1 month post-treatment. Data are means ± 
SEM (n=12 animals/group). *p<0.05, **p<0.01vs vehicle; Student’s t test. 
 
4.12 Effect of curcumin on BDNF mRNA levels in LPS-treated mice. 
To investigate possible effect of curcumin on BDNF mRNA levels in the LPS-
induced inflammatory state, mice were treated with curcumin and LPS, sacrificed 
2 hours, 24 hours and 7 days post-treatment and brain areas collected for real-time 
RT-PCR analysis, as previously described (see “Materials and Methods” section). 
Basal levels of BDNF gene expression was not affected by curcumin treatment. 
Conversely, LPS treatment significantly reduced BDNF gene expression starting 
from 2 hours after treatment in all brain areas analysed, with the exception of 
striatum, where low levels of BDNF mRNA were found. Pre-treatment with 50 
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mg/kg curcumin  restored BDNF mRNA levels to control values 24 hours after 
LPS injection (Fig. 35). Interestingly, a higher dose of curcumin (100 mg/Kg) 
significantly recovered LPS-induced decrease of BDNF gene expression to 
control values 2 hours after LPS injection, showing a dose- and time-dependent 
effect of curcumin (data not shown). 
  
Figure 35: Effect of curcumin on BDNF mRNA levels in different brain areas. Mice were 
treated for 2 consecutive days with a single daily dose of 50 mg/Kg curcumin before LPS 
treatment. mRNA levels of BDNF were evaluated 2 hours, 24 hours and 7 days after treatment 
with LPS in frontal cortex, striatum, hippocampus and cerebellum, by real-time RT-PCR. Data 
are means ± SEM (n=6 animals/group). *p<0.05, **p<0.01, ***p<0.001 vs vehicle; 
###
p<0.001 
vs LPS treatment. ANOVA followed by post-hoc Tukey’s test. 
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5. Discussion 
Innate immune response is emerging as a crucial component of major 
neurodegenerative diseases. Microglia are resident immune cells in the CNS that 
can be activated in response to injurious stimuli, infection, misfolded proteins or 
aberrantly localized nucleic acids, contributing to neuroinflammation. Activated 
microglia secrete pro-inflammatory mediators, that aggravate and propagate 
neuroinflammation contributing to neuronal cell damage and loss and impaired 
brain functions in both animal models and human patients [Heneka et al., 2014, 
Réus et al., 2015]. Therefore, inhibition of neuroinflammation and microglial 
activation may represent valuable strategic targets for therapeutic intervention in 
neurological disorders associated with inflammation. In recent years, research has 
focused on the study of anti-inflammatory agents in in vivo experimental models 
of neuroinflammation. 
The in vivo mouse model used in this study has been realized through a single 
intraperitoneal injection of LPS (5 mg/kg) in adult male mice. This model is 
widely used for studying neuroinflammatory processes in rodents and its use is 
supported by the knowledge that an acute inflammatory condition is essential for 
the occurrence of a state of chronic inflammation [Medzhitov, 2010]. Moreover, 
the 5 mg/Kg dose of LPS is capable of inducing neurodegeneration, without 
causing animals death [Liya et al., 2007]. A comparison between two doses of 
LPS (0.5 and 5 mg/Kg), in terms of gene expression changes of pro-inflammatory 
molecules (TNF-α, IL-1β, IL-6, IL-18, COX-2 and iNOS) was performed to verify 
if the lower dose also induced neuroinflammation and subsequent 
neurodegeneration. High dose of LPS induced a significantly increase in gene 
expression of almost all the inflammatory molecules analyzed, 2 hours after 
injection. IL-18 mRNA levels were not modified after LPS treatment, probably 
because this cytokine follows different kinetics of activation that other members 
of IL-1-family [Felderhoff-Mueser et al., 2005]. Conversely, low dose of LPS (0.5 
mg/kg) did not induce any significantly increase in gene expression of 
inflammatory molecules, although it was able to induce a state of sickness 
behavior, characterized by a reduction in body weight and food intake, 
comparable to the higher dose of LPS.  
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After molecular characterization of the in vivo model of neuroinflammation, the 
anti-inflammatory and possible neuroprotective effect of curcumin was tested. 
Extensive research and clinical trials over the past half century have shown that 
curcumin can modulate multiple cell signalling pathways involved in 
neuroinflammation. Anti-inflammatory properties of curcumin are linked to 
numerous molecular mechanisms [He et al., 2015], involving also its ability to 
antagonize the binding of LPS with its binding site in the TLR4. Binding of LPS 
activates the inflammatory intracellular signalling, leading to activation of 
transcription factor NF-κB, which controls the final immune response through the 
synthesis of inflammatory molecules [Lu et al., 2008].  
A treatment protocol was first developed in order to optimize the effects of 
curcumin in mice. Since this molecule is poorly water soluble, it was administered 
using a daily administration, for 2 consecutive days, via gavage in a 1% 
methylcellulose suspension, leaving the animals fasted overnight in order to 
increase curcumin absorption [Begum et al., 2008]. Given the low bioavailability 
of curcumin, initially we verified whether this molecule could cross the BBB to 
enter brain tissue. HPLC-MS analysis showed that curcumin entered unmodified 
brain tissue 3 hours after oral administration, reaching clinically relevant 
concentrations (1.80 ± 0.50 µg/g). Conversely, 3 hours after administration, 
plasma concentration of curcumin was very low (1.32 ± 0.17 ng/ml); furthermore, 
some glucuronide metabolites were detected as biotransformation products in 
plasma samples of curcumin, confirming previously published studies [Anand et 
al., 2007].Then, a dose-response study was performed administering three doses 
of curcumin (5, 10 and 50 mg/kg) that were tested for their anti-inflammatory 
properties, in terms of prevention of pro-inflammatory gene expression increase 
induced by LPS. Only 50 mg/Kg curcumin significantly reduced the LPS-induced 
increase of mRNA levels of several pro-inflammatory molecules (TNF-α, IL-1β, 
IL-6 and COX-2) in different brain areas (cortex, striatum, hippocampus and 
cerebellum). This dose of curcumin is widely used in the scientific literature; in 
particular, a mouse daily dose of 50 mg/Kg curcumin corresponds to 3.5 g/day for 
a man weighing 70 Kg, which is considered a safe dose, because dose-escalating 
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studies have indicated the safety of curcumin at dose as high as 12 g/day over 3 
months [Chainani-Wu , 2003].  
An important aspect of neuroinflammatory response is the activation of microglial 
cells that can assume different phenotypes depending on the type of stimulation. 
Microglial activation consists in morphological changes, followed by functional 
changes, characterized by increased expression of membrane receptors and by the 
release of pro-inflammatory molecules, which support the inflammatory process 
[Melinda et al., 2010]. Curcumin pre-treatment completely prevented LPS-
induced microglial morphological changes, as demonstrated by 
immunohistochemical analysis, showing cells characterized by a small cell body 
and many thin ramifications, similar to that of the control mice. 
An excessive neuroinflammatory response can alter brain functions and lead to 
brain pathologies. Many studies have suggested the onset of motor and memory 
deficits induced by a neuroinflammatory state [Robert et al., 2008]. In this study, 
a locomotor activity test was carried out to assess the effect of curcumin  on LPS-
induced motor deficit. LPS-treated mice showed a significant decrease in total 
distance traveled 24 hours and 7 days after injection, while pre-treatment with 
curcumin significantly prevented LPS-induced motor deficits. Several studies 
suggest that motor deficits induced by LPS can be related to an altered 
functionality of voluntary movement control centers, such as basal ganglia, which 
use dopaminergic and glutamatergic neurons as principal connections [Martyn, 
2009]. Moreover, dopaminergic neurons are very sensitive to cerebral 
microenvironment and easily degenerate in response to traumas or inflammatory 
processes [Drui, 2014]. To test the effect of neuroinflammation on neuronal 
survival, a TH-immunohistochemistry of dopaminergic neurons within the 
substantia nigra pars compacta and ventral tegmental area 7 days after LPS 
injection was performed. LPS injection decreased the number of dopaminergic 
neurons in the substantia nigra pars compacta and ventral tegmental area, which 
could be related to the observed motor dysfunction in LMA paradigm. Further 
studies evaluating the effect of neuroinflammation in other neuronal cell types 
involved in motor control are needed to confirm this relationship. Interestingly, 
curcumin treatment prevented dopaminergic neuronal cell loss, suggesting a 
 87 
 
possible neuroprotective effect of this molecule that can be used in the treatment 
of brain pathologies associated with motor deficits, such as Parkinson disease. 
Molecular mechanisms underlying neuroprotective effect of curcumin are multiple 
and may involve several neurotrophic factors, including BDNF, especially in 
terms of synaptic plasticity [Calabrese et al., 2014]. The BDNF synthesis occurs 
ubiquitously in the brain, with the exception of some areas, such as striatum where 
BDNF is anterogradely transported from cell bodies located in the cerebral cortex, 
substantia nigra, amygdala and thalamus [Baydyuk and Xu, 2014]. LPS induced a 
significant reduction of BDNF gene expression levels up to 7 days after treatment, 
in cerebral cortex, hippocampus and cerebellum, whereas in striatum mRNA of 
BDNF appeared to be absent. Pre-treatment with curcumin restored BDNF mRNA 
expression to control values, in a dose- and time-dependent manner, suggesting a 
possible neuroprotective role of curcumin. To further confirm these results BDNF 
protein levels should be measured.  
Finally, based on previous observations showing that “sickness behavior” induced 
by LPS includes alterations in central processes involved in learning and memory 
[Song et al., 2013], the presence of possible memory deficits in the LPS-induced 
inflammatory state was evaluated. To this aim,  a behavioral test (novel object 
recognition) which discriminates the differences in the exploration time of novel 
and familiar objects [Antunes and Biala, 2012] was used. Our preliminary 
observations showed a reduction in the ability to discriminate novel objects, 
induced by LPS, suggesting a link between neuroinflammation and the onset of 
mnesic deficits. Further studies will be needed to study the possible protective 
effect of curcumin. 
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6. Conclusions 
The results reported in this thesis show the importance of curcumin as an in vivo 
anti-inflammatory agent, able to modulate microglial activation and CNS 
inflammatory processes. 
 
In particular, curcumin protected against LPS-induced: 
 
 gene expression increase of TNF-α, IL-1β, IL-6 and COX-2 in different 
brain areas; 
 increase of TNF-α protein levels; 
 microglial morphological “activation”; 
 behavioral symptoms of sickness, such as reduction of body weight and 
food intake; 
 mouse motor deficits; 
 dopaminergic neuron loss in substantia nigra pars compacta and ventral 
tegmental area; 
 gene expression changes of BDNF in different brain areas. 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 36: Anti-inflammatory and neuroprotective properties of curcumin. 
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Taken together, these data support the idea that pharmacological strategies aimed 
at decreasing neuroinflammation associated with microglial activation are 
important for improving recovery from sickness and reducing neurobehavioral 
deficits. 
These results may also provide useful information to develop novel therapeutic 
approaches for neurodegenerative diseases, that represent a growing unmet 
medical need, given the increasing shift in population dynamics and longevity. 
Current treatment at best represent a symptomatic approach, while disease-
modifying therapeutics remain to be successfully developed. More work will be 
needed to establish the relevance of curcumin anti-inflammatory effects observed 
in animal models to its clinical effects and to elucidate the precise molecular 
mechanisms underlying the anti-inflammatory and neuroprotective effects of this 
natural molecule. A more complete understanding of these issues would promote 
the design of novel curcumin derivatives with improved availability and 
therapeutic efficacy, for the management of neurological diseases associated with 
inflammation. 
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Don’t get stuck in the “comparison trap”.  
Just challenge yourself everyday  
and keep getting better and better…  
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